

# Edoardo Savarino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3921776/publications.pdf>

Version: 2024-02-01

657  
papers

20,951  
citations

15466

65  
h-index

16605

123  
g-index

667  
all docs

667  
docs citations

667  
times ranked

10985  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid Drink Challenge During High-resolution Manometry for Evaluation of Esophageal Emptying in Treated Achalasia. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 55-63.	2.4	9
2	Association between postâ€reflux swallowâ€induced peristaltic wave index and esophageal mucosal integrity in patients with GERD symptoms. <i>Neurogastroenterology and Motility</i> , 2023, 35, e14344.	1.6	4
3	Relevance of Excessive Air Swallowing in GERD Patients With Concomitant Functional Dyspepsia and Poor Response to PPI Therapy. <i>Journal of Clinical Gastroenterology</i> , 2023, 57, 466-471.	1.1	2
4	Autoimmune gastritis: long-term natural history in naÃve<i>Helicobacter pylori</i>-negative patients. <i>Gut</i> , 2023, 72, 30-38.	6.1	39
5	Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter. <i>Updates in Surgery</i> , 2023, 75, 291-303.	0.9	5
6	High-Resolution Manometry Thresholds and Motor Patterns Among Asymptomatic Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e398-e406.	2.4	23
7	Episodeâ€level reflux characteristics: How experienced reviewers differentiate true reflux from artifact on pHâ€impedance studies. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14153.	1.6	10
8	Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e89-e101.	2.4	17
9	Reflux characteristics triggering postâ€reflux swallowâ€induced peristaltic wave (PSPW) in patients with GERD symptoms. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14183.	1.6	10
10	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 659-670.	1.5	40
11	Primary Hypogammaglobulinaemia with Inflammatory Bowel Disease-Like Features: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 91-97.	0.6	6
12	Application of Lyon Consensus criteria for GORD diagnosis: evaluation of conventional and new impedance-pH parameters. <i>Gut</i> , 2022, 71, 1062-1067.	6.1	32
13	Placebo Response Rates in Trials of Licensed Drugs for Irritable Bowel Syndrome With Constipation or Diarrhea: Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e923-e944.	2.4	22
14	Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation. <i>Intestinal Research</i> , 2022, 20, 114-123.	1.0	12
15	Epstein-Barr virus associated gastric dysplasia: a new rare entity?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 480, 939-944.	1.4	3
16	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 179-189.	0.6	120
17	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 2-17.	0.6	288
18	Risk Prediction and Comparative Efficacy of Anti-TNF vs Thiopurines, for Preventing Postoperative Recurrence in Crohn's Disease: A Pooled Analysis of 6 Trials. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2741-2752.e6.	2.4	18

#	ARTICLE	IF	CITATIONS
19	Question Prompt List as a Communication Tool for Adults With Gastroesophageal Reflux Disease. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 565-570.	1.1	3
20	Adverse events in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: Systematic review and meta-analysis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14279.	1.6	6
21	Artificial Intelligence in the Diagnosis of Upper Gastrointestinal Diseases. <i>Journal of Clinical Gastroenterology</i> , 2022, 56, 23-35.	1.1	22
22	Biliary Tree Diagnostics: Advances in Endoscopic Imaging and Tissue Sampling. <i>Medicina (Lithuania)</i> , 2022, 58, 135.	0.8	4
23	Systematic review with meta-analysis: artificial intelligence in the diagnosis of oesophageal diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 528-540.	1.9	27
24	P044 Enteric dopaminergic pathways in mouse and human intestinal inflammation. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i160-i161.	0.6	0
25	P119 Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicenter Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i210-i210.	0.6	0
26	Gastroesophageal reflux disease: key messages for clinicians. <i>Minerva Gastroenterology</i> , 2022, 67, .	0.3	4
27	EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210742.	1.4	13
28	P014 Impact of experimental ileitis and Toll-Like Receptor 4 signaling on enteric inhibitory neurotransmission. <i>Journal of Crohn's and Colitis</i> , 2022, 16, i142-i142.	0.6	0
29	Systematic Review: esophageal motility patterns in patients with eosinophilic esophagitis. <i>Digestive and Liver Disease</i> , 2022, 54, 1143-1152.	0.4	20
30	A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach. <i>Gut Microbes</i> , 2022, 14, 2028366.	4.3	26
31	Toward a potential association between eosinophilic esophagitis and Klinefelter syndrome: a case series and review of the literature. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210768.	1.4	1
32	Applying Lyon Consensus criteria in the work-up of patients with proton pump inhibitory refractory heartburn. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1423-1430.	1.9	24
33	Eosinophilic esophagitis: novel concepts regarding pathogenesis and clinical manifestations. <i>Minerva Gastroenterology</i> , 2022, 68, .	0.3	6
34	Pharmacotherapies in eosinophilic esophagitis: state of the art. <i>Minerva Gastroenterology</i> , 2022, 68, 69-76.	0.3	0
35	Nonachalasic esophageal motor disorders, from diagnosis to therapy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2022, 16, 205-216.	1.4	2
36	Eosinophilic esophagitis: a rising disease. <i>Minerva Gastroenterology</i> , 2022, 68, .	0.3	0

#	ARTICLE	IF	CITATIONS
37	Letter: the potential link between oesophageal hypervigilance, visceral anxiety, increased swallow rate and oesophageal mucosal integrity. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 756-757.	1.9	2
38	Mismatch repair status and gastroesophageal dysplasia: need for a dedicated gastrointestinal pathologist?. <i>Histopathology</i> , 2022, , .	1.6	2
39	Serum oncostatin M predicts mucosal healing in patients with inflammatory bowel diseases treated with anti-TNF, but not vedolizumab. <i>Digestive and Liver Disease</i> , 2022, 54, 1367-1373.	0.4	10
40	The present and future of gastroenterology and hepatology: an international SWOT analysis (the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.7	9
41	Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series. <i>Pathology Research and Practice</i> , 2022, 233, 153872.	1.0	1
42	Integrated Relaxation Pressure Classification and Probe Positioning Failure Detection in High-Resolution Esophageal Manometry Using Machine Learning. <i>Sensors</i> , 2022, 22, 253.	2.1	4
43	Gastroenteropancreatic Neuroendocrine Neoplasms in Patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 940-945.	0.6	5
44	Editorial: Lyon consensus metricsâ€”towards personalised diagnosis of nonâ€”erosive reflux disease: Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1216-1217.	1.9	0
45	OC.05.4 SYSTEMATIC REVIEW WITH META-ANALYSIS: ARTIFICIAL INTELLIGENCE IN THE DIAGNOSIS OF ESOPHAGEAL DISEASES. <i>Digestive and Liver Disease</i> , 2022, 54, S80-S81.	0.4	0
46	Achalasia. <i>Nature Reviews Disease Primers</i> , 2022, 8, 28.	18.1	36
47	T.01.1 APPLICATION OF LYON CONSENSUS CRITERIA FOR GERD DIAGNOSIS: EVALUATION OF PATIENTS WITH INCONCLUSIVE DIAGNOSIS AND NEW IMPEDANCE-PH PARAMETERS. <i>Digestive and Liver Disease</i> , 2022, 54, S115.	0.4	0
48	Effectiveness and safety of vedolizumab in a matched cohort of elderly and nonelderly patients with inflammatory bowel disease: the <sc>IGâ€”BD LIVE</sc> study. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 95-109.	1.9	25
49	Small intestine neuromuscular dysfunction in a mouse model of dextran sulfate sodium-induced ileitis: Involvement of dopaminergic neurotransmission. <i>Life Sciences</i> , 2022, 301, 120562.	2.0	1
50	Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of the EoE CONNECT Registry. <i>United European Gastroenterology Journal</i> , 2022, 10, 507-517.	1.6	19
51	Towards a more precise classification of esophageal motility disorders in patients with systemic sclerosis. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14416.	1.6	1
52	Advances on Neurogastroenterology and Motility Disorders: Pathophysiology, Diagnostics and Management. <i>Journal of Clinical Medicine</i> , 2022, 11, 2911.	1.0	1
53	Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naïve patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. <i>Lancet, The</i> , 2022, 399, 2200-2211.	6.3	94
54	Salivary microbiota composition may discriminate between patients with eosinophilic oesophagitis (<sc>EoE</sc>) and <sc>nonâ€”EoE</sc> subjects. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 450-462.	1.9	8

#	ARTICLE	IF	CITATIONS
55	Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. <i>United European Gastroenterology Journal</i> , 2022, 10, 556-584.	1.6	40
56	Chicago classification v4.0 protocol improves specificity and accuracy of diagnosis of oesophagogastric junction outflow obstruction. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 606-613.	1.9	16
57	Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1845-1852.	0.6	5
58	Management of <i>Helicobacter pylori</i> infection: Guidelines of the Italian Society of Gastroenterology (SIGE) and the Italian Society of Digestive Endoscopy (SIED). <i>Digestive and Liver Disease</i> , 2022, 54, 1153-1161.	0.4	24
59	Real-time determination of gastric juice pH with EndoFaster <sup>®</sup> for atrophic gastritis assessment. <i>Digestive and Liver Disease</i> , 2022, 54, 1646-1648.	0.4	5
60	Automated Chicago Classification for Esophageal Motility Disorder Diagnosis Using Machine Learning. <i>Sensors</i> , 2022, 22, 5227.	2.1	2
61	Advancements in the use of 24-hour impedance-pH monitoring for GERD diagnosis. <i>Current Opinion in Pharmacology</i> , 2022, 65, 102264.	1.7	4
62	Inter-reviewer Variability in Interpretation of pH-Impedance Studies: The Wingate Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1976-1978.e1.	2.4	45
63	Duodenal Histological Findings and Risk of Coeliac Disease in Subjects with Autoimmune Atrophic Gastritis: A Retrospective Evaluation. <i>Digestion</i> , 2021, 102, 615-621.	1.2	6
64	Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world. <i>Gut</i> , 2021, 70, 1441-1449.	6.1	49
65	Achalasia and Obstructive Motor Disorders Are Not Uncommon in Patients With Eosinophilic Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1554-1563.	2.4	34
66	Inflammatory Bowel Disease and Sleep Disturbance: As Usual, Quality Matters. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3-4.	1.1	13
67	A Peculiar Cutaneous Manifestation in a Patient With Crohn's Disease. <i>Gastroenterology</i> , 2021, 160, e1-e3.	0.6	1
68	Elimination of Dietary Triggers Is Successful in Treating Symptoms of Gastroesophageal Reflux Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 1565-1571.	1.1	21
69	Artificial intelligence automates and augments baseline impedance measurements from pH-impedance studies in gastroesophageal reflux disease. <i>Journal of Gastroenterology</i> , 2021, 56, 34-41.	2.3	24
70	Immunolocalization of leptin and leptin receptor in colorectal mucosa of ulcerative colitis, Crohn's disease and control subjects with no inflammatory bowel disease. <i>Cell and Tissue Research</i> , 2021, 383, 1103-1122.	1.5	6
71	The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?. <i>Gastroenterology</i> , 2021, 160, 1903-1904.	0.6	3
72	Dual Targeted Therapy: A Possible Option for the Management of Refractory Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 335-339.	0.6	37

#	ARTICLE	IF	CITATIONS
73	Upper gastrointestinal bleeding in COVID-19 inpatients: Incidence and management in a multicenter experience from Northern Italy. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101521.	0.7	55
74	Esophagogastric junction morphology and contractile integral on high-resolution manometry in asymptomatic healthy volunteers: An international multicenter study. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14009.	1.6	10
75	Cyclosporin or Infliximab as Rescue Therapy in Acute Glucocorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 733-741.	0.6	10
76	European Society for Neurogastroenterology and Motility (ESNM) recommendations for the use of high-resolution manometry of the esophagus. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14043.	1.6	15
77	Reply Letter to "Oral butyrate modulates the gut microbiota in patients with inflammatory bowel disease, most likely by reversing proinflammatory metabolic reprogramming of colonocytes". <i>Neurogastroenterology and Motility</i> , 2021, 33, e14054.	1.6	0
78	Effects of SARS-CoV-2 emergency measures on high-risk lesions detection: a multicentre cross-sectional study. <i>Gut</i> , 2021, 70, 1241-1243.	6.1	8
79	Should Patients With Inflammatory Bowel Disease Be Tested for Active COVID-19 Before Starting a Biological Treatment?. <i>Gastroenterology</i> , 2021, 160, 2626-2627.	0.6	1
80	Postreflux swallow-induced peristaltic wave index from pH-impedance monitoring associates with esophageal body motility and esophageal acid burden. <i>Neurogastroenterology and Motility</i> , 2021, 33, e13973.	1.6	14
81	Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482199990.	1.4	16
82	Esophageal pH increments associated with post-reflux swallow-induced peristaltic waves show the occurrence and relevance of esophago-salivary reflex in clinical setting. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14085.	1.6	20
83	Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 1184-1196.	0.6	26
84	A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110314.	1.4	10
85	Response to Khalaf et al.. <i>American Journal of Gastroenterology</i> , 2021, 116, 1565-1566.	0.2	0
86	Low Levels of Gastrin 17 are Related with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 25-29.	0.5	3
87	Gastrointestinal mucosal damage in patients with COVID-19 undergoing endoscopy: an international multicentre study. <i>BMJ Open Gastroenterology</i> , 2021, 8, e000578.	1.1	49
88	Impact of the Sars-Cov-2 Pandemic on Gastroenterology Units in Italy: a National Survey. , 2021, 53, .		0
89	Development of quality indicators for the diagnosis and management of achalasia. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14118.	1.6	9
90	Chicago Classification Update (v4.0): Technical review on diagnostic criteria for hypercontractile esophagus. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14115.	1.6	19

#	ARTICLE	IF	CITATIONS
91	Diagnostic yield and reliability of postprandial high-resolution manometry and impedance-pH for detecting rumination and supragastric belching in PPI nonresponders. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14106.	1.6	3
92	Objective Evidence of Gastro-Esophageal Reflux Disease is Rare in Patients with Autoimmune Gastritis. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2021, 30, 30-36.	0.5	2
93	MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. <i>Biomedicines</i> , 2021, 9, 318.	1.4	7
94	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>United European Gastroenterology Journal</i> , 2021, 9, 307-331.	1.6	62
95	Bariatric Surgery and Esophageal Function: An Eternal Impasse?. <i>American Journal of Gastroenterology</i> , 2021, 116, 1754-1755.	0.2	1
96	Management of Osteoarthritis: Expert Opinion on NSAIDs. <i>Pain and Therapy</i> , 2021, 10, 783-808.	1.5	40
97	Eosinophilic Esophagitis and Achalasia: Are We Putting All the Pieces Together?. <i>American Journal of Gastroenterology</i> , 2021, 116, 1759-1759.	0.2	2
98	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. <i>United European Gastroenterology Journal</i> , 2021, 9, 287-306.	1.6	60
99	Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art. <i>Drug Design, Development and Therapy</i> , 2021, Volume 15, 1609-1621.	2.0	21
100	Manometric pattern progression in esophageal achalasia in the era of high-resolution manometry. <i>Annals of Translational Medicine</i> , 2021, 9, 906-906.	0.7	2
101	Patients With Definite and Inconclusive Evidence of Reflux According to Lyon Consensus Display Similar Motility and Esophagogastric Junction Characteristics. <i>Journal of Neurogastroenterology and Motility</i> , 2021, 27, 565-573.	0.8	7
102	N11 Complementary and alternative methods to improve quality of life in patients with inflammatory bowel diseases: a systematic literature review. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S613-S614.	0.6	0
103	DOP79 Primary hypogammaglobulinemia with IBD-like features: An ECCO CONFER Multicenter Case Series. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S111-S111.	0.6	1
104	Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. <i>Scientific Reports</i> , 2021, 11, 10368.	1.6	21
105	Prevention Strategies for Esophageal Cancer—An Expert Review. <i>Cancers</i> , 2021, 13, 2183.	1.7	19
106	Faecal Microbiome Transplantation as a Solution to Chronic Enteropathies in Dogs: A Case Study of Beneficial Microbial Evolution. <i>Animals</i> , 2021, 11, 1433.	1.0	12
107	P329 Comparative Assessment of Adalimumab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S353-S353.	0.6	0
108	P506 The Impact of Anxiety in Patients With Inflammatory Bowel Diseases Treated With Biologics during COVID Lockdown. A Comparative Study between Hospitalized and non-hospitalized patients. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S487-S488.	0.6	0

#	ARTICLE	IF	CITATIONS
109	P295 Comparative Assessment of Infliximab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S325-S325.	0.6	0
110	P216 Comparative Assessment C-reactive Protein Between a Point-of-Care Testing and Current Standard of Care (Immunonephelometric testing). <i>Journal of Crohn's and Colitis</i> , 2021, 15, S272-S273.	0.6	0
111	Refractoriness to Treatment Suggests That Clinical Evaluation Should Go Beyond the Diagnosis of Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1077-1078.	2.4	0
112	P124 Gastroenteropancreatic Neuroendocrine Neoplasms in patients with Inflammatory Bowel Disease: An ECCO CONFER Multicentre Case Series. <i>Journal of Crohn's and Colitis</i> , 2021, 15, S215-S216.	0.6	0
113	Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach. <i>Nutrients</i> , 2021, 13, 1630.	1.7	21
114	Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 359-370.	3.7	256
115	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 2914.	1.0	8
116	Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis—more questions than answers? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 190-191.	1.9	0
117	ID: 3522469 RISK OF COVID-19 TRANSMISSION AND OUTCOMES IN HEALTHCARE WORKERS PRESENT DURING GASTROINTESTINAL ENDOSCOPIC PROCEDURES: AN INTERNATIONAL MULTICENTER STUDY. <i>Gastrointestinal Endoscopy</i> , 2021, 93, AB45-AB46.	0.5	0
118	Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastroesophageal reflux disease according to Lyon Consensus. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 412-418.	1.9	42
119	Increased visceral sensitivity, elevated anxiety, and depression levels in patients with functional esophageal disorders and non-erosive reflux disease. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14177.	1.6	17
120	Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence. <i>Cancers</i> , 2021, 13, 3162.	1.7	35
121	Diagnostic delay and misdiagnosis in eosinophilic oesophagitis. <i>Digestive and Liver Disease</i> , 2021, 53, 1632-1639.	0.4	28
122	Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis. <i>Digestive and Liver Disease</i> , 2021, 53, 1479-1485.	0.4	30
123	Sarcopenia, severe anxiety and increased C-reactive protein are associated with severe fatigue in patients with inflammatory bowel diseases. <i>Scientific Reports</i> , 2021, 11, 15251.	1.6	5
124	Editorial: inconclusive diagnosis of GERD: are new parameters in impedance-pHmetry ready for clinical use? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 498-499.	1.9	2
125	Hospitalisation for Drug Infusion Did Not Increase Levels of Anxiety and the Risk of Disease Relapse in Patients with Inflammatory Bowel Disease during COVID-19 Outbreak. <i>Journal of Clinical Medicine</i> , 2021, 10, 3270.	1.0	1
126	Value of pH Impedance Monitoring While on Twice-Daily Proton Pump Inhibitor Therapy to Identify Need for Escalation of Reflux Management. <i>Gastroenterology</i> , 2021, 161, 1412-1422.	0.6	27

#	ARTICLE	IF	CITATIONS
127	Therapeutic drug monitoring in Crohn's disease patients treated with anti-TNF. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, Publish Ahead of Print, .	0.8	3
128	Exploring the association between esophageal mucosal inflammation, impaired motility, and GERD severity. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14211.	1.6	2
129	Global prevalence of functional constipation according to the Rome criteria: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 638-648.	3.7	105
130	Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2021, 161, 1865-1877.	0.6	46
131	How a modified Nissen procedure works: a mechanistic study using intraoperative esophageal high-resolution manometry. <i>Langenbeck's Archives of Surgery</i> , 2021, , 1.	0.8	1
132	Letter: is wireless oesophageal pH monitoring the best technique to evaluate nighttime reflux?. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 974-975.	1.9	1
133	OC.01.10 EGJ OUTFLOW OBSTRUCTION ACCORDING TO THE NEW CHICAGO CLASSIFICATION: HOW MANY DIAGNOSES MIGHT BE CONFIRMED?. <i>Digestive and Liver Disease</i> , 2021, 53, S97.	0.4	0
134	Molecular Landscapes of Gastric Pre-Neoplastic and Pre-Invasive Lesions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9950.	1.8	11
135	An update of pharmacology, efficacy, and safety of vonoprazan in acid-related disorders. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, , 1-10.	1.4	4
136	AF.15 EOSINOPHILIC ESOPHAGITIS IS FREQUENTLY ASSOCIATED WITH DISORDERS OF PERISTALSIS AT HIGH-RESOLUTION MANOMETRY: A PROSPECTIVE SINGLE-CENTRE CASE-CONTROL STUDY. <i>Digestive and Liver Disease</i> , 2021, 53, S143-S144.	0.4	0
137	AF.48 COMPARATIVE ASSESSMENT OF ADALIMUMAB TROUGH LEVELS BETWEEN POINT-OF-CARE TESTING AND CURRENT STANDARD OF CARE (ENZYME LINKED IMMUNOSORBENT ASSAY) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. <i>Digestive and Liver Disease</i> , 2021, 53, S158.	0.4	0
138	Endoscopic tissue sampling – Part 1: Upper gastrointestinal and hepatopancreatobiliary tracts. <i>European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy</i> , 2021, 53, 1174-1188.	1.0	71
139	United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14238.	1.6	21
140	OC.01.5 RAPID DRINK CHALLENGE DURING HIGH RESOLUTION MANOMETRY IS USEFUL TO PREDICT ESOPHAGEAL EMPTYING IN ACHALASIA PATIENTS AFTER TREATMENT. <i>Digestive and Liver Disease</i> , 2021, 53, S94-S95.	0.4	0
141	Gastritis: The clinico-pathological spectrum. <i>Digestive and Liver Disease</i> , 2021, 53, 1237-1246.	0.4	30
142	Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110233.	1.4	7
143	Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482098086.	1.4	40
144	Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance-pH parameters implying anti-reflux mechanism of action. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 1183-1189.	1.9	15

#	ARTICLE	IF	CITATIONS
145	Esophageal motility disorders on high-resolution manometry: Chicago classification version 4.0. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14058.	1.6	468
146	ESNM/ANMS consensus paper: Diagnosis and management of refractory gastroesophageal reflux disease. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14075.	1.6	68
147	Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study. <i>Digestive Diseases</i> , 2021, 39, 16-24.	0.8	12
148	Symptom Stability in Rome IV vs Rome III Irritable Bowel Syndrome. <i>American Journal of Gastroenterology</i> , 2021, 116, 362-371.	0.2	34
149	Hypercontractile Esophagus From Pathophysiology to Management: Proceedings of the Pisa Symposium. <i>American Journal of Gastroenterology</i> , 2021, 116, 263-273.	0.2	24
150	The tapestry of reflux syndromes: translating new insight into clinical practice. <i>British Journal of General Practice</i> , 2021, 71, 470-473.	0.7	6
151	Influence of <i>Tilia tomentosa</i> Moench Extract on Mouse Small Intestine Neuromuscular Contractility. <i>Nutrients</i> , 2021, 13, 3505.	1.7	4
152	The Risk of Malignancies in Celiac Disease—A Literature Review. <i>Cancers</i> , 2021, 13, 5288.	1.7	15
153	Endoscopic tissue sampling – Part 2: Lower gastrointestinal tract. European Society of Gastrointestinal Endoscopy (ESGE) Guideline. <i>Endoscopy</i> , 2021, 53, 1261-1273.	1.0	30
154	Refractory Gastroesophageal Reflux Disease: A Management Update. <i>Frontiers in Medicine</i> , 2021, 8, 765061.	1.2	34
155	Not All Autoimmune Gastritis Are Created the Same. <i>Gastroenterology Research</i> , 2021, 14, 348-349.	0.4	4
156	Derivation and validation of a novel method to subgroup patients with functional dyspepsia: beyond upper gastrointestinal symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 253-264.	1.9	8
157	Esophageal High-Resolution Manometry Can Unravel the Mechanisms by Which Different Bariatric Techniques Produce Different Reflux Exposures. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1-7.	0.9	37
158	Mean Nocturnal Baseline Impedance Correlates With Symptom Outcome When Acid Exposure Time Is Inconclusive on Esophageal Reflux Monitoring. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 589-595.	2.4	66
159	Gastrointestinal: An unusual rectal finding in a patient with ulcerative colitis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 179-179.	1.4	5
160	Matrix Metalloproteinase 3 Predicts Therapeutic Response in Inflammatory Bowel Disease Patients Treated With Infliximab. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 756-763.	0.9	21
161	Interstitial and Granulomatous Lung Disease in Inflammatory Bowel Disease Patients. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 480-489.	0.6	26
162	Development and Validation of a Test to Monitor Endoscopic Activity in Patients With Crohn's Disease Based on Serum Levels of Proteins. <i>Gastroenterology</i> , 2020, 158, 515-526.e10.	0.6	65

#	ARTICLE	IF	CITATIONS
163	Correlation between reflux burden, peristaltic function, and mucosal integrity in GERD patients. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13752.	1.6	27
164	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 4-22.	0.6	741
165	Fragmented and failed swallows on esophageal high-resolution manometry associate with abnormal reflux burden better than weak swallows. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13736.	1.6	32
166	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 155-168.	0.6	478
167	Diagnosis and Outcome of Oesophageal Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 624-629.	0.6	2
168	Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2397-2402.	1.1	6
169	Factors associated with disability in patients with ulcerative colitis: A cross-sectional study. <i>Journal of Digestive Diseases</i> , 2020, 21, 81-87.	0.7	10
170	Quality-of-Life Evaluation in Coeliac Patients on a Gluten-Free Diet. <i>Nutrients</i> , 2020, 12, 2981.	1.7	16
171	PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 3134.	1.0	19
172	Development of a Preliminary Question Prompt List as a Communication Tool for Adults With Gastroesophageal Reflux Disease. <i>Journal of Clinical Gastroenterology</i> , 2020, 54, 857-863.	1.1	5
173	A further step forward in our knowledge of the pathogenetic role of gastroesophageal reflux in pulmonary fibrosis. <i>Digestive and Liver Disease</i> , 2020, 52, 986-987.	0.4	1
174	Telemedicine and Remote Screening for COVID-19 in Inflammatory Bowel Disease Patients: Results From the SoCOVID-19 Survey. <i>Inflammatory Bowel Diseases</i> , 2020, 26, e134-e136.	0.9	6
175	Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nocere. <i>Digestive and Liver Disease</i> , 2020, 52, 1248-1249.	0.4	1
176	The hypercontractile esophagus: Still a tough nut to crack. <i>Neurogastroenterology and Motility</i> , 2020, 32, e14010.	1.6	9
177	Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2790-2792.e1.	2.0	9
178	P415 The anti-IL-23/IL-12 agent Ustekinumab is an effective and safe induction therapy in patients with Crohn's disease refractory or intolerant to anti-TNF: a multicentre Italian study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S379-S379.	0.6	2
179	P465 Therapeutic drug monitoring in Crohn's disease patients, a comparison between homogeneous mobility shift assay and point of care method. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S412-S412.	0.6	0
180	Reorganization of the functional gastrointestinal disorders unit during the SARS-CoV-2 outbreak - Practical Recommendations. <i>Digestive and Liver Disease</i> , 2020, 52, 1097-1098.	0.4	0

#	ARTICLE	IF	CITATIONS
181	Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care. United European Gastroenterology Journal, 2020, 8, 1228-1235.	1.6	16
182	Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093431.	1.4	6
183	Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2020, 5, 908-917.	3.7	359
184	Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093653.	1.4	13
185	Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. Alimentary Pharmacology and Therapeutics, 2020, 52, 798-807.	1.9	72
186	Tu1336 REFLUX MONITORING WITH IMPEDANCE-PHMETRY: NEW SET OF NORMAL VALUES OBTAINED FROM CONSENSUS ANALYSIS OF TRACINGS FROM HEALTHY ASYMPTOMATIC SUBJECTS. A MULTICENTRE INTERNATIONAL COLLABORATIVE STUDY. PRELIMINARY RESULTS. Gastroenterology, 2020, 158, S-1064-S-1065.	0.6	1
187	Systematic review with meta-analysis: global prevalence of uninvestigated dyspepsia according to the Rome criteria. Alimentary Pharmacology and Therapeutics, 2020, 52, 762-773.	1.9	29
188	P668 Real-life comparison of different anti-TNF biologic therapies for ulcerative colitis treatment: A retrospective cohort study. Journal of Crohn's and Colitis, 2020, 14, S548-S549.	0.6	0
189	Esophageal reflux hypersensitivity: Non-GERD or still GERD?. Digestive and Liver Disease, 2020, 52, 1413-1420.	0.4	16
190	Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482093458.	1.4	7
191	T01.02.4 FECAL EOSINOPHIL CATIONIC PROTEIN AS POTENTIAL MARKER OF DISEASE ACTIVITY IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS. Digestive and Liver Disease, 2020, 52, S63-S64.	0.4	0
192	T01.02.8 EOSINOPHILIC ESOPHAGITIS - VISUAL SCORE: A NOVEL PICTORIAL SELF-ADMINISTERED TOOL TO ASSESS QUALITY OF LIFE IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS. Digestive and Liver Disease, 2020, 52, S65-S66.	0.4	0
193	T01.02.17 CLINICAL USEFULNESS OF SECOND-GENERATION BARRIER DRUGS IN GERD PATIENTS WITH ATYPICAL SYMPTOMS: A-6-MONTHS PROSPECTIVE STUDY. Digestive and Liver Disease, 2020, 52, S69-S70.	0.4	0
194	T01.02.19 IS IT POSSIBLE TO WITHDRAW PPIS THERAPY IN GERD PATIENTS? A PROSPECTIVE STUDY ON 216 PATIENTS USING A SECOND GENERATION BARRIER DRUG. Digestive and Liver Disease, 2020, 52, S70-S71.	0.4	0
195	T01.02.21 ESOPHAGEAL MOTILITY DISORDERS IN EOSINOPHILIC ESOPHAGITIS. Digestive and Liver Disease, 2020, 52, S71-S72.	0.4	1
196	T01.02.23 ROLE OF ENVIRONMENTAL FACTORS ON THE OUTCOME OF GASTROESOPHAGEAL REFLUX DISEASE: 6 MONTHS PROSPECTIVE STUDY. Digestive and Liver Disease, 2020, 52, S72-S73.	0.4	0
197	T04.02.8 INFLIXIMAB ORIGINATOR, INFLIXIMAB BIOSIMILAR AND ADALIMUMAB ARE EQUALLY EFFECTIVE AND SAFE IN ULCERATIVE COLITIS AND CROHN'S DISEASE - A REAL-LIFE COHORT STUDY. Digestive and Liver Disease, 2020, 52, S130-S131.	0.4	0
198	An "Old" Esophagus. American Journal of Gastroenterology, 2020, 115, 1389-1389.	0.2	3

#	ARTICLE	IF	CITATIONS
199	Use of the Functional Lumen Imaging Probe in Clinical Esophagology. American Journal of Gastroenterology, 2020, 115, 1786-1796.	0.2	84
200	Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice. Digestive and Liver Disease, 2020, 52, 1252-1253.	0.4	0
201	Risk of COVID-19 in celiac disease patients. Autoimmunity Reviews, 2020, 19, 102639.	2.5	23
202	No need of transforming gastroenterology units to covid units at the time of SARS-COV2 infection - a single-center analysis from northern italy. Digestive and Liver Disease, 2020, 52, 1094-1096.	0.4	1
203	COVID-19 pandemic perception in adults with celiac disease: an impulse to implement the use of telemedicine. Digestive and Liver Disease, 2020, 52, 1071-1075.	0.4	60
204	Impact of the COVID-19 pandemic on Gastroenterology Divisions in Italy: A national survey. Digestive and Liver Disease, 2020, 52, 808-815.	0.4	54
205	Starting a Biologic Therapy in IBD Patients Amid COVID-19: Hold, Careful Monitoring, or Testing?. Journal of Crohn's and Colitis, 2020, 14, 1785-1785.	0.6	5
206	Endoscopic management of gastrointestinal motility disorders " part 1: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2020, 52, 498-515.	1.0	75
207	Endoscopic management of gastrointestinal motility disorders " part 2: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2020, 52, 600-614.	1.0	70
208	Microbiota changes induced by microencapsulated sodium butyrate in patients with inflammatory bowel disease. Neurogastroenterology and Motility, 2020, 32, e13914.	1.6	68
209	There is much more to rely on histology than the sole endoscopy tells us. Gut, 2020, 69, 1709-1710.	6.1	2
210	European Society for Neurogastroenterology and Motility recommendations for conducting gastrointestinal motility and function testing in the recovery phase of the COVID-19 pandemic. Neurogastroenterology and Motility, 2020, 32, e13930.	1.6	15
211	Medical and gastroenterological education during the COVID-19 outbreak. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 447-449.	8.2	18
212	Latest insights into the hot question of proton pump inhibitor safety " a narrative review. Digestive and Liver Disease, 2020, 52, 842-852.	0.4	25
213	Appropriateness of proton pump inhibitors treatment in clinical practice: Prospective evaluation in outpatients and perspective assessment of drug optimisation. Digestive and Liver Disease, 2020, 52, 862-868.	0.4	11
214	A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring. Digestive and Liver Disease, 2020, 52, 966-980.	0.4	27
215	Reply to Letter to the Editor: NLR and PLR as Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF. Inflammatory Bowel Diseases, 2020, 26, e104-e104.	0.9	1
216	P843 Intestinal microbiota changes according to disease activity in patients with ulcerative colitis. Journal of Crohn's and Colitis, 2020, 14, S651-S652.	0.6	0

#	ARTICLE	IF	CITATIONS
217	Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 525.	3.7	37
218	P468 Switching from adalimumab originator to ABP 501 biosimilar: a multicentre North Italian study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S414-S414.	0.6	1
219	High-resolution Manometry Determinants of Refractoriness of Reflux Symptoms to Proton Pump Inhibitor Therapy. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 447-454.	0.8	19
220	Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak. <i>Journal of Clinical Medicine</i> , 2020, 9, 2011.	1.0	16
221	The Lyon Consensus: Does It Differ From the Previous Ones?. <i>Journal of Neurogastroenterology and Motility</i> , 2020, 26, 311-321.	0.8	26
222	Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00177.	1.3	14
223	99P Association of gut microbiome diversity and composition with pathological complete response (pCR) after neoadjuvant chemotherapy in triple negative breast cancer. <i>Annals of Oncology</i> , 2020, 31, S50.	0.6	0
224	Bile reflux in patients with nerd is associated with more severe heartburn and lower values of mean nocturnal baseline impedance and chemical clearance. <i>Neurogastroenterology and Motility</i> , 2020, 32, e13919.	1.6	23
225	Patient dissatisfaction with medical therapy for chronic constipation or irritable bowel syndrome with constipation: analysis of 1 prospective trials in 81 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 629-636.	1.9	23
226	Sleep disturbance in Inflammatory Bowel Disease: prevalence and risk factors – A cross-sectional study. <i>Scientific Reports</i> , 2020, 10, 507.	1.6	42
227	Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2903-2911.e4.	2.4	51
228	P438 Real-life effectiveness and safety of ABP501, an adalimumab biosimilar, in inflammatory bowel disease: a multicentre Italian study. <i>Journal of Crohn's and Colitis</i> , 2020, 14, S397-S397.	0.6	0
229	&#x26;p&#x27;Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data&#x26;p&#x27;. <i>Clinical and Experimental Gastroenterology</i> , 2020, Volume 13, 99-104.	1.0	14
230	Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1579-1587.	0.9	39
231	Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak. <i>Digestive and Liver Disease</i> , 2020, 52, 604-605.	0.4	15
232	Pathophysiology, diagnosis, and pharmacological treatment of gastro-esophageal reflux disease. <i>Expert Review of Clinical Pharmacology</i> , 2020, 13, 437-449.	1.3	21
233	A Survey on Nutritional Knowledge in Coeliac Disease Compared to Inflammatory Bowel Diseases Patients and Healthy Subjects. <i>Nutrients</i> , 2020, 12, 1110.	1.7	4
234	The coeliac stomach: A review of the literature. <i>Digestive and Liver Disease</i> , 2020, 52, 615-624.	0.4	4

#	ARTICLE	IF	CITATIONS
235	Editorial: symptom improvement does not equal satisfaction with treatment for constipation—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 910-911.	1.9	2
236	Post-reflux swallow-induced peristaltic wave (PSPW): physiology, triggering factors and role in reflux clearance in healthy subjects. <i>Journal of Gastroenterology</i> , 2020, 55, 1109-1118.	2.3	23
237	Comparison of Two Different Techniques to Assess Adalimumab Trough Levels in Patients with Crohn's Disease. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 24, 451-456.	0.5	21
238	Perception of the COVID-19 Pandemic Among Patients With Inflammatory Bowel Disease in the Time of Telemedicine: Cross-Sectional Questionnaire Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e19574.	2.1	15
239	Usefulness of Pep-Test for Laryngo-Pharyngeal Reflux: A Pilot Study in Primary Care. <i>Korean Journal of Family Medicine</i> , 2020, 41, 250-255.	0.4	7
240	The Role of Wireless Capsule Endoscopy (WCE) in the Detection of Occult Primary Neuroendocrine Tumors. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 26, 151-156.	0.5	14
241	OC.11.6 POOR CORRELATION BETWEEN ENDOSCOPIC FINDINGS, EOSINOPHILIC INFILTRATION AND REFLUX BURDEN IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS. <i>Digestive and Liver Disease</i> , 2019, 51, e108.	0.4	0
242	P.01.2 ESOPHAGO-GASTRIC JUNCTION CONTRACTILE INTEGRAL (EGJ-CI) MAY PREDICT RESPONSE TO TREATMENT IN PATIENTS WITH ESOPHAGEAL ACHALASIA. <i>Digestive and Liver Disease</i> , 2019, 51, e132-e133.	0.4	0
243	How to select patients for antireflux surgery? The ICARUS guidelines (international consensus) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 1</i>	6.1	80
244	Jackhammer esophagus with and without esophagogastric junction outflow obstruction demonstrates altered neural control resembling type 3 achalasia. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13678.	1.6	27
245	The prevention of NSAID-induced gastric ulcers is a firmly established PPI indication. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 1011-1012.	1.3	1
246	"Let's Make Your Clinic Visit a Little Simpler" Development of a Question Prompt List for Adult Patients With Gastroesophageal Reflux Disease: a Modified Delphi Study. <i>Gastroenterology</i> , 2019, 157, e25-e26.	0.6	0
247	Updates in the field of non-esophageal gastroesophageal reflux disorder. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 827-838.	1.4	31
248	P697 <i>Pneumocystis jirovecii</i> pneumonia in IBD patients treated with immunomodulator(s). <i>Journal of Crohn's and Colitis</i> , 2019, 13, S468-S469.	0.6	1
249	P.01.31 A COMPARISON OF DIFFERENT TREATMENTS FOR SYMPTOMATIC REFLUX ESOPHAGITIS: A REAL-LIFE STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e145-e146.	0.4	0
250	A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. <i>Nutrition</i> , 2019, 67-68, 110542.	1.1	42
251	P650 Mechanisms of Infliximab failure: the predictive role of MMP3. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S444-S444.	0.6	1
252	OC.12.4 RAPID POINT-OF-CARE MONITORING OF ANTI-INFLIXIMAB ANTIBODIES AND CLINICAL SCORES IN INFLAMMATORY BOWEL DISEASE PATIENTS. <i>Digestive and Liver Disease</i> , 2019, 51, e110-e111.	0.4	0

#	ARTICLE	IF	CITATIONS
253	P.01.12 ON-THERAPY PARAMETERS RATHER THAN OFF-THERAPY IMPEDANCE-PH FEATURES BETTER IDENTIFY PATIENTS WITH NON-EROSIVE REFLUX DISEASE RESPONDING TO PROTON PUMP INHIBITOR THERAPY. Digestive and Liver Disease, 2019, 51, e138.	0.4	0
254	P.02.35 INTESTINAL INVOLVEMENT IN WEGENER'S GRANULOMATOSIS MIMICKING AN INFLAMMATORY BOWEL DISEASE: A CASE REPORT. Digestive and Liver Disease, 2019, 51, e162-e163.	0.4	0
255	P.07.2 DISEASE ACTIVITY INFLUENCES DISABILITY AND QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE " A CROSS-SECTIONAL STUDY. Digestive and Liver Disease, 2019, 51, e221-e222.	0.4	0
256	P.07.17 EFFICACY AND SAFETY OF VEDOLIZUMAB IN REAL LIFE: EXPERIENCE IN A TERTIARY REFERRAL CENTRE. Digestive and Liver Disease, 2019, 51, e229.	0.4	0
257	P.07.28 PREVIOUS EXPOSURE TO INFLIXIMAB INDUCES CROSS-REACTIVITY AND AFFECTS ADALIMUMAB TROUGH LEVELS: DATA FROM A PROSPECTIVE, MULTICENTRE STUDY. Digestive and Liver Disease, 2019, 51, e234.	0.4	0
258	Efficacy of teduglutide in a patient with Crohn's disease and short bowel syndrome on enteral nutrition: let's start to think out of the box. Gastroenterology Report, 2019, 7, 459-460.	0.6	4
259	N18 Mood disorders in a IBD population: a single-centre cohort. Journal of Crohn's and Colitis, 2019, 13, S565-S565.	0.6	0
260	OC.09.3 INFLIXIMAB DOSE-REDUCTION IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS IN PROLONGED DEEP REMISSION: POTENTIAL IMPLICATIONS ON DE-ESCALATION STRATEGIES IN A REAL LIFE CLINICAL SETTING WITHOUT A THERAPEUTIC DRUG MONITORING (TDM) APPROACH. Digestive and Liver Disease, 2019, 51, e101.	0.4	0
261	High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2019, 54, 1220-1225.	0.6	6
262	P.07.22 HIGH RESOLUTION ANORECTAL MANOMETRY FOR DETERMINATION OF ANORECTAL FUNCTION IN ULCERATIVE COLITIS DURING DISEASE ACTIVITY AND AFTER REMISSION. Digestive and Liver Disease, 2019, 51, e231.	0.4	0
263	OC.10.1 NOVEL MII-PH PARAMETERS ARE ABLE TO DISTINGUISH PATIENTS WITH GERD AMONG SUBJECT WITH EXTRA-ESOPHAGEAL SYMPTOMS. Digestive and Liver Disease, 2019, 51, e103.	0.4	0
264	<p></p>Idiopathic pulmonary fibrosis and GERD: links and risks<p></p>. Therapeutics and Clinical Risk Management, 2019, Volume 15, 1081-1093.	0.9	42
265	P.01.25 CAN A NON-INVASIVE TEST PREDICT THE RESULTS OF PH-IMPEDANCE? PROSPECTIVE STUDY OF A COHORT OF PATIENTS WITH EXTRA-ESOPHAGEAL MANIFESTATIONS OF GERD. Digestive and Liver Disease, 2019, 51, e143-e144.	0.4	0
266	Factors Influencing Disability and Quality of Life during Treatment: A Cross-Sectional Study on IBD Patients. Gastroenterology Research and Practice, 2019, 2019, 1-10.	0.7	37
267	Esophageal mucosal innervation in functional heartburn: Closer to healthy asymptomatic subjects than to non-erosive reflux disease patients. Neurogastroenterology and Motility, 2019, 31, e13667.	1.6	20
268	OC.12.1 REAL-LIFE EFFECTIVENESS OF USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH CONCOMITANT PSORIASIS OR PSORIATIC ARTHRITIS: AN IG-IBD STUDY. Digestive and Liver Disease, 2019, 51, e109.	0.4	0
269	OC.03.3 THE "DICA" ENDOSCOPIC CLASSIFICATION FOR DIVERTICULAR DISEASE OF THE COLON SHOWS A SIGNIFICANT INTEROBSERVER AGREEMENT AMONG COMMUNITY ENDOSCOPISTS. Digestive and Liver Disease, 2019, 51, e84.	0.4	0
270	P.01.9 EFFECTIVENESS OF PEPSINO®, A NOVEL MEDICAL DEVICE CONTAINING HYALURONIC ACID AND ALGINATE, FOR THE TREATMENT OF LARYNGOPHARYNGEAL REFLUX SYMPTOMS. Digestive and Liver Disease, 2019, 51, e136-e137.	0.4	0

#	ARTICLE	IF	CITATIONS
271	P.07.32 THE QUALITY OF SLEEP IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS IMPAIRED INDEPENDENTLY FROM THE DISEASE ACTIVITY STATUS – A CROSS-SECTIONAL STUDY. <i>Digestive and Liver Disease</i> , 2019, 51, e236.	0.4	0
272	P.01.8 PROVOCATIVE TESTS DURING HIGH-RESOLUTION MANOMETRY MAY BE HELPFUL TO DISTINGUISH PATIENTS WITH EOSINOPHILIC ESOPHAGITIS RESPONDING TO PPI THERAPY. <i>Digestive and Liver Disease</i> , 2019, 51, e136.	0.4	0
273	P.01.22 A NATIONAL SURVEY ON GASTROENTEROLOGY TRAINING IN ITALY: CURRENT LANDSCAPE AND FUTURE NEEDS. <i>Digestive and Liver Disease</i> , 2019, 51, e142.	0.4	0
274	Sleeve Gastrectomy, GERD, and Barrett’s Esophagus: It Is Time for Objective Testing. <i>Obesity Surgery</i> , 2019, 29, 2312-2313.	1.1	9
275	The treatment of achalasia patients with esophageal varices: an international study. <i>United European Gastroenterology Journal</i> , 2019, 7, 565-572.	1.6	10
276	P.07.33 MICROENCAPSULATED SODIUM BUTYRATE SIGNIFICANTLY MODIFIES THE MICROBIOTA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE MIMICKING PREBIOTIC ACTIVITY AND PROVING EFFECTS ON THE TREATMENT OF THE DISEASE. <i>Digestive and Liver Disease</i> , 2019, 51, e236-e238.	0.4	0
277	Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study. <i>Digestive and Liver Disease</i> , 2019, 51, 972-977.	0.4	25
278	Opioid Treatment and Excessive Alcohol Consumption Are Associated With Esophagogastric Junction Disorders. <i>Journal of Neurogastroenterology and Motility</i> , 2019, 25, 205-211.	0.8	9
279	P232 Oesophageal Crohn’s disease: diagnosis and outcome of an ECCO-CONFER case series. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S212-S213.	0.6	0
280	Advancements in the use of manometry and impedance testing for esophageal functional disorders. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 425-435.	1.4	10
281	Quantification of visceral adipose tissue by computed tomography and magnetic resonance imaging: reproducibility and accuracy. <i>Radiologia Brasileira</i> , 2019, 52, 1-6.	0.3	28
282	P.07.4 HIGH ANTI-TNF ALFA DRUGS TROUGH LEVELS ARE NOT ASSOCIATED WITH THE OCCURRENCE OF ADVERSE EVENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. <i>Digestive and Liver Disease</i> , 2019, 51, e223.	0.4	0
283	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). <i>Digestive and Liver Disease</i> , 2019, 51, 632-639.	0.4	36
284	P541 Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S384-S385.	0.6	0
285	Ineffective esophageal motility: Concepts, future directions, and conclusions from the Stanford 2018 symposium. <i>Neurogastroenterology and Motility</i> , 2019, 31, e13584.	1.6	76
286	Gastric fundal splenosis presenting as a stromal tumor and diagnosed by endoscopic ultrasound-guided SharkCore biopsy. <i>Endoscopy</i> , 2019, 51, E160-E161.	1.0	2
287	P475 Rapid point-of-care anti-drug antibodies measurement correlates with standardised T tests and facilitate a proactive therapeutic drug monitoring approach in IBD patients on anti-TNF- $\alpha$ maintenance therapy. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S349-S350.	0.6	2
288	Esophagogastric junction function and gastric pressure profile after minigastric bypass compared with Billroth II. <i>Surgery for Obesity and Related Diseases</i> , 2019, 15, 567-574.	1.0	10

#	ARTICLE	IF	CITATIONS
289	P655 Microencapsulated Sodium Butyrate significantly modifies the microbiota in patients with inflammatory bowel disease mimicking prebiotic activity and proving effects on the treatment of the disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S446-S447.	0.6	2
290	Weak Cytotoxic T Cells Activation Predicts Low-Grade Dysplasia Persistence in Ulcerative Colitis. <i>Clinical and Translational Gastroenterology</i> , 2019, 10, e00061.	1.3	2
291	Role of Reflux in the Pathogenesis of Eosinophilic Esophagitis: Comprehensive Appraisal With Off- and On PPI Impedance-pH Monitoring. <i>American Journal of Gastroenterology</i> , 2019, 114, 1606-1613.	0.2	42
292	Antimicrobial treatment with the fixed-dose antibiotic combination RHB-104 for <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> in Crohn's disease: pharmacological and clinical implications. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 79-88.	1.4	14
293	Provocative testing in patients with jackhammer esophagus: evidence for altered neural control. <i>American Journal of Physiology - Renal Physiology</i> , 2019, 316, G397-G403.	1.6	27
294	Superior Mesenteric Artery Syndrome: a Prospective Study in a Single Institution. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 997-1005.	0.9	38
295	Authors' reply. <i>Annals of Gastroenterology</i> , 2019, 32, 319.	0.4	0
296	The "DICA" Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 23-27.	0.5	6
297	Vonoprazan May Provide Better Results than PPIs in Helicobacter Pylori Eradication and Beyond "Is it Time for a Change?". <i>Journal of Gastrointestinal and Liver Diseases</i> , 2019, 28, 375-377.	0.5	1
298	Long-Term Safety of In Utero Exposure to Anti-TNF± Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study. <i>American Journal of Gastroenterology</i> , 2018, 113, 396-403.	0.2	134
299	Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study. <i>Digestive Diseases</i> , 2018, 36, 264-268.	0.8	22
300	Lack of improvement of impaired chemical clearance characterizes PPI-refractory reflux-related heartburn. <i>American Journal of Gastroenterology</i> , 2018, 113, 670-676.	0.2	60
301	Curriculum for neurogastroenterology and motility training: A report from the joint ANMS-ESNM task force. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13341.	1.6	15
302	Modern diagnosis of GERD: the Lyon Consensus. <i>Gut</i> , 2018, 67, 1351-1362.	6.1	991
303	Infliximab trough levels and persistent vs transient antibodies measured early after induction predict long-term clinical remission in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2018, 50, 452-456.	0.4	22
304	P.07.11 LOW FODMAP DIET IMPROVE DISEASE ACTIVITY AND QUALITY OF LIFE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. <i>Digestive and Liver Disease</i> , 2018, 50, e197-e198.	0.4	1
305	A modified Nissen fundoplication: subjective and objective midterm results. <i>Langenbeck's Archives of Surgery</i> , 2018, 403, 279-287.	0.8	2
306	P.02.12 MICROBIOTA PROFILE AND DYSBIOSIS ASSESSMENT IN CLINICAL PRACTICE: A PILOT STUDY ON IBD PATIENTS. <i>Digestive and Liver Disease</i> , 2018, 50, e137.	0.4	0

#	ARTICLE	IF	CITATIONS
307	Helicobacter Pylori Infection Does Not Protect Against Eosinophilic Esophagitis: Results From a Large Multicenter Case-Control Study. <i>American Journal of Gastroenterology</i> , 2018, 113, 972-979.	0.2	52
308	Quality of life after laparoscopic sigmoid resection for uncomplicated diverticular disease. <i>International Journal of Colorectal Disease</i> , 2018, 33, 513-523.	1.0	16
309	Psoriasis and small intestine bacterial overgrowth. <i>International Journal of Dermatology</i> , 2018, 57, 112-113.	0.5	21
310	Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1365-1372.	1.5	208
311	Letter: oesophageal histological abnormalities and <scp>GERD</scp> â€•an underestimated relationship requiring more attention. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 152-153.	1.9	0
312	Bowel Sonoelastography in Patients with Crohn's Disease: A Systematic Review. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 297-302.	0.7	21
313	The natural history of achalasia: Evidence of a continuumâ€”â€œThe evolutive pattern theoryâ€•. <i>Digestive and Liver Disease</i> , 2018, 50, 342-347.	0.4	22
314	Optimal number of multiple rapid swallows needed during highâ€•resolution esophageal manometry for accurate prediction of contraction reserve. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13253.	1.6	44
315	Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 569-574.	1.6	5
316	P.07.26 QUALITY OF LIFE ASSESSMENT IN ULCERATIVE COLITIS OUTPATIENTS: A CROSS SECTIONAL STUDY. <i>Digestive and Liver Disease</i> , 2018, 50, e204.	0.4	0
317	Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. <i>Annals of Gastroenterology</i> , 2018, 31, 639-648.	0.4	68
318	P.06.26 RISK FACTORS IN GERD: A COMPARATIVE STUDY WITH DYSPEPTIC SUBJECTS ON 2300 PEOPLE IN A PRIMARY CARE SETTING. <i>Digestive and Liver Disease</i> , 2018, 50, e190.	0.4	0
319	P.10.24 VISCERAL ADIPOSE TISSUE QUANTIFICATION ON COMPUTED TOMOGRAPHY AND MAGNETIC RESONANCE IMAGES: REPRODUCIBILITY AND ACCURACY. <i>Digestive and Liver Disease</i> , 2018, 50, e238.	0.4	0
320	OC.09.3 DYSPHAGIA IS A DRIVEN SYMPTOM ABLE TO PREDICT PERSISTENT EGJ-OUTFLOW OBSTRUCTION DURING A SIX-MONTH FOLLOW-UP: HRM STUDY WITH PROVOCATIVE TEST. <i>Digestive and Liver Disease</i> , 2018, 50, e90.	0.4	0
321	P.07.19 MR-ENTEROGRAPHY WITH AND WITHOUT CONTRAST MEDIA INJECTION: RETROSPECTIVE EVALUATION IN PATIENTS AFFECTED BY CROHN'S DISEASE. <i>Digestive and Liver Disease</i> , 2018, 50, e201.	0.4	0
322	Proton pump inhibitors: use and misuse in the clinical setting. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1123-1134.	1.3	112
323	Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in nonâ€•erosive reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1074-1081.	1.9	32
324	Glucose transporter expression in the human colon. <i>World Journal of Gastroenterology</i> , 2018, 24, 775-793.	1.4	23

#	ARTICLE	IF	CITATIONS
325	P.06.14 EFFECTIVENESS AND SAFETY OF PYLERA Â® IN PATIENTS INFECTED BY HELICOBACTER PYLORI: A LARGE, PROSPECTIVE, REAL LIFE STUDY. <i>Digestive and Liver Disease</i> , 2018, 50, e184-e185.	0.4	0
326	OC.16.5 IMPACT OF ADALIMUMAB'S PATIENT SUPPORT PROGRAM ON ADHERENCE TO ANTI-TNF-ALFA THERAPY IN INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER ANALYSIS. <i>Digestive and Liver Disease</i> , 2018, 50, e110.	0.4	0
327	P.06.2 PROTON PUMP INHIBITOR THERAPY IMPROVES ESOPHAGEAL SYMPTOMS BY RESTORING A NORMAL ESOPHAGEAL PERISTALSIS IN PPI-REE. <i>Digestive and Liver Disease</i> , 2018, 50, e179.	0.4	1
328	OLGA Gastritis Staging for the Prediction of Gastric Cancer Risk: A Long-term Follow-up Study of 7436 Patients. <i>American Journal of Gastroenterology</i> , 2018, 113, 1621-1628.	0.2	96
329	P.07.3 EFFECTIVENESS OF GOLIMUMAB IN REAL LIFE â€” A SINGLE CENTER PROSPECTIVE STUDY. <i>Digestive and Liver Disease</i> , 2018, 50, e193-e194.	0.4	1
330	The 2018 ISDE achalasia guidelines. <i>Ecological Management and Restoration</i> , 2018, 31, .	0.2	221
331	Eosinophilic esophagitis: latest insights from diagnosis to therapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 84-93.	1.8	20
332	Nonerosive reflux disease: clinical concepts. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 290-303.	1.8	11
333	Current and future perspectives in the management of gastroesophageal reflux disease. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 70-83.	1.8	12
334	Indications and interpretation of esophageal function testing. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 239-253.	1.8	43
335	OC.06.5 LOW-FODMAP DIET RESULTED EFFECTIVE IN REDUCING SYMPTOM PERCEPTION IN PATIENTS WITH FUNCTIONAL HEARTBURN: RANDOMIZED, CROSS-OVER CONTROLLED STUDY. <i>Digestive and Liver Disease</i> , 2018, 50, e82-e83.	0.4	0
336	OC.09.5 THE NATURAL HISTORY OF ACHALASIA: EVIDENCE OF A CONTINUUM â€” THE EVOLUTIVE PATTERN THEORYâ€” <i>Digestive and Liver Disease</i> , 2018, 50, e91.	0.4	0
337	Vegetal and Animal Food Proteins Have a Different Impact in the First Postprandial Hour of Impedance-pH Analysis in Patients with Heartburn. <i>Gastroenterology Research and Practice</i> , 2018, 2018, 1-7.	0.7	17
338	Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) â€” Study section â€” Digestive Diseases in Primary Careâ€” <i>Digestive and Liver Disease</i> , 2018, 50, 894-902.	0.4	30
339	Highâ€”resolution manometry is superior to endoscopy and radiology in assessing and grading sliding hiatal hernia: A comparison with surgical inâ€”vivo evaluation. <i>United European Gastroenterology Journal</i> , 2018, 6, 981-989.	1.6	55
340	Letter: it is time to adopt new objective parameters to accurately identify patients with functional heartburn. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 107-108.	1.9	2
341	A safety review of proton pump inhibitors to treat acid-related digestive diseases. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 785-794.	1.0	24
342	P.06.9 MULTIPLE RAPID SWALLOW MIGHT BE HELPFUL TO IMPROVE THE DIAGNOSIS OF INEFFECTIVE ESOPHAGEAL MOTILITY. <i>Digestive and Liver Disease</i> , 2018, 50, e182.	0.4	0

#	ARTICLE	IF	CITATIONS
343	P.06.5 ESOMEPRAZOLE, RABEPRAZOLE AND PANTOPRAZOLE ARE EQUALLY EFFECTIVE IN INDUCING ENDOSCOPIC AND HISTOLOGIC REMISSION IN PATIENTS WITH PROTON PUMP INHIBITOR-RESPONSE ESOPHAGEAL EOSINOPHILIA. <i>Digestive and Liver Disease</i> , 2018, 50, e180-e181.	0.4	1
344	Effects of bariatric surgery on the esophagus. <i>Current Opinion in Gastroenterology</i> , 2018, 34, 243-248.	1.0	12
345	The "three-in-one" formulation of bismuth quadruple therapy for <i>Helicobacter pylori</i> eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice. <i>Helicobacter</i> , 2018, 23, e12502.	1.6	39
346	The appropriate use of proton-pump inhibitors. <i>Minerva Medica</i> , 2018, 109, 386-399.	0.3	46
347	Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn. <i>Journal of Gastroenterology</i> , 2017, 52, 444-451.	2.3	96
348	P.01.13: Gastrin-17 as a Non-Invasive Marker for Gerd: A Prospective Study on Sample of 777 Consecutive Patients. <i>Digestive and Liver Disease</i> , 2017, 49, e137.	0.4	0
349	Proximal Esophageal Baseline Impedance Levels are Able to Discriminate between Scleroderma Patients with and without Esophageal Involvement. <i>Gastroenterology</i> , 2017, 152, S654.	0.6	0
350	The Natural History of Achalasia: Evidence of a Continuum and the Pattern-Evolutive Staging Theory. <i>Gastroenterology</i> , 2017, 152, S702-S703.	0.6	1
351	Esophageal chemical clearance and baseline impedance values in patients with chronic autoimmune atrophic gastritis and gastro-esophageal reflux disease. <i>Digestive and Liver Disease</i> , 2017, 49, 978-983.	0.4	12
352	Adalimumab Therapy Rather than Azathioprine and Mesalamine is Able to Halt Crohn's Disease Progression after Resectiver Surgery and a Post-Hoc Analysis of a Prospective Randomized Study. <i>Gastroenterology</i> , 2017, 152, S774.	0.6	3
353	Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease?. <i>Digestive and Liver Disease</i> , 2017, 49, 728-730.	0.4	18
354	The Effect of Sleeve Gastrectomy on Esophageal Chemical Clearance and Basal Impedance Values. <i>Gastroenterology</i> , 2017, 152, S236.	0.6	0
355	High Resolution Manometry is Superior to Endoscopy and Radiology in Assessing and Grading Sliding Hiatal Hernia. A Prospective Comparison with Surgical in vivo. <i>Gastroenterology</i> , 2017, 152, S3.	0.6	1
356	Step-Up Empiric Elimination Diet for Pediatric and Adult Eosinophilic Esophagitis: The 2-4-6 Study. <i>Gastroenterology</i> , 2017, 152, S207.	0.6	8
357	Classification of esophageal motor findings in gastroesophageal reflux disease: Conclusions from an international consensus group. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13104.	1.6	158
358	Postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance can link <sc>PPI</sc>-responsive heartburn to reflux better than acid exposure time. <i>Neurogastroenterology and Motility</i> , 2017, 29, e13116.	1.6	107
359	OC.15.4: High Resolution Manometry Should be Considered the best Test to Diagnose Sliding Hiatal Hernia. <i>Digestive and Liver Disease</i> , 2017, 49, e121-e122.	0.4	0
360	Influence of Diet on the Course of Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2087-2094.	1.1	44

#	ARTICLE	IF	CITATIONS
361	Impedance-pH Monitoring for Diagnosis of Reflux Disease: New Perspectives. <i>Digestive Diseases and Sciences</i> , 2017, 62, 1881-1889.	1.1	66
362	Different Proton Pump Inhibitors are Equally Effective in Inducing Endoscopic and Histologic Remission in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia. <i>Gastroenterology</i> , 2017, 152, S860-S861.	0.6	0
363	Ambulatory reflux monitoring for diagnosis of gastroesophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. <i>Neurogastroenterology and Motility</i> , 2017, 29, 1-15.	1.6	275
364	Effects of laparoscopic myotomy on the esophageal motility pattern of esophageal achalasia as measured by high-resolution manometry. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2017, 31, 3510-3518.	1.3	13
365	A modification of Nissen fundoplication improves patients' outcome and may reduce procedure-related failure rate. <i>International Journal of Surgery</i> , 2017, 38, 83-89.	1.1	7
366	Eosinophilic esophagitis: Update in diagnosis and management. Position paper by the Italian Society of Gastroenterology and Gastrointestinal Endoscopy (SIGE). <i>Digestive and Liver Disease</i> , 2017, 49, 254-260.	0.4	43
367	PWE-129 Treatment of achalasia in patients with oesophageal varices: an international case series. , 2017, , .		0
368	Symptom perception in patients with NERD: do nerves matter?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 634-636.	8.2	2
369	P.O2.1: Individual Assessment of Gastric Acid Production by Means of a Non-Invasive Test: Relationship Between Maximal Acid Output and Serum Pepsinogen I Levels in Patients with Different Upper GI Diseases. <i>Digestive and Liver Disease</i> , 2017, 49, e138.	0.4	0
370	OC.15.1: High-Volume Rapid Drinking test Better Distinguishes Esophageal Body Inhibition Compared to Low-Volume Multiple Rapid Swallows. <i>Digestive and Liver Disease</i> , 2017, 49, e120-e121.	0.4	0
371	OC.15.2: Low-Volume Multiple Rapid Swallow Better Distinguishes Peristaltic Esophageal Reserve Compared to High-Volume Rapid Drinking Test. <i>Digestive and Liver Disease</i> , 2017, 49, e121.	0.4	0
372	P.O1.11: Gastrin 17 in Singling out Patients with Different Pattern of Gastroesophageal Reflux: A Pilot Study using PH-Impedance as Reference Standard. <i>Digestive and Liver Disease</i> , 2017, 49, e136.	0.4	0
373	P.O1.14: Overweight and Obesity as Risk Factors for Gerd Outcome: A 10 Years Study on a Gerd Population of 365 Patients. <i>Digestive and Liver Disease</i> , 2017, 49, e137.	0.4	0
374	P.11.10: Does LÃ©mann Index Reflect the Quality of Life in Crohnâ€™s Disease Patients on Treatment with Biological Therapy?. <i>Digestive and Liver Disease</i> , 2017, 49, e206.	0.4	0
375	High-Volume Rapid Drinking Test Better Distinguish Esophageal Body Inhibition Compared to Low-Volume Multiple Rapid Swallows. <i>Gastroenterology</i> , 2017, 152, S695.	0.6	0
376	P.O1.12: The Abdominal Length of Lower Esophageal Sphincter is Inversely Correlated with Abnormal Esophageal Acid Exposure. <i>Digestive and Liver Disease</i> , 2017, 49, e136.	0.4	0
377	The Effect of Bile Reflux on Baseline Impedance Value and Chemical Clearance in Patients with NERD. <i>Gastroenterology</i> , 2017, 152, S654.	0.6	1
378	Vigor of Contraction is Directly Related to Esophageal Chemical Clearance (PSPW Index). <i>Gastroenterology</i> , 2017, 152, S654-S655.	0.6	0

#	ARTICLE	IF	CITATIONS
379	Low-Volume Multiple Rapid Swallow Better Distinguish Peristaltic Esophageal Reserve Compared to High-Volume Rapid Drinking Test. <i>Gastroenterology</i> , 2017, 152, S694.	0.6	0
380	Low-FODMAP Diet Resulted Effective in Relieving Esophageal and Intestinal Symptoms in Patients with Pathophysiological Characteristics of Functional Heartburn and a Prospective, Interventional Study. <i>Gastroenterology</i> , 2017, 152, S751.	0.6	0
381	OC.15.5: Post-Reflux Swallow-Induced Peristaltic wave Index and Mean Nocturnal Baseline Impedance Predict Heartburn Response to Proton PUMP Inhibitors Better than Acid Exposure Time. <i>Digestive and Liver Disease</i> , 2017, 49, e122.	0.4	0
382	P.01.2: Changes in Esophageal Chemical Clearance and Basal Impedance Values after Sleeve Gastrectomy. <i>Digestive and Liver Disease</i> , 2017, 49, e131-e132.	0.4	0
383	P.01.4: The Effect of Bile Reflux on Baseline Impedance and Chemical Clearance in Patients with Nerd. <i>Digestive and Liver Disease</i> , 2017, 49, e132-e133.	0.4	0
384	P.01.6: Vigor of Contraction is Directly Related to Esophageal Chemical Clearance (PSPW Index). <i>Digestive and Liver Disease</i> , 2017, 49, e133-e134.	0.4	0
385	Post-Reflux Swallow-Induced Peristaltic Wave Index and Mean Nocturnal Baseline Impedance Predict Heartburn Response to Proton Pump Inhibitors Better than Acid Exposure Time in GERD. <i>Gastroenterology</i> , 2017, 152, S652-S653.	0.6	0
386	Gastrin 17 in Singling Out Patients with Different Patterns of Refluxate: A Pilot Study Using Impedance-pH as Reference Standard. <i>Gastroenterology</i> , 2017, 152, S653.	0.6	1
387	Proton Pump Inhibitor Therapy Improves Esophageal Symptoms by Restoring a Normal Esophageal Peristalsis in Patients with Proton Pump Inhibitor-Response Esophageal Eosinophilia. <i>Gastroenterology</i> , 2017, 152, S860.	0.6	0
388	Evaluation of Esophagogastric Junction Contractility after Different Treatments for Achalasia. <i>Gastroenterology</i> , 2017, 152, S1242.	0.6	0
389	A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD). <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1333-1343.	0.9	39
390	What to eat and drink in the festive season. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 608-614.	0.8	10
391	OC.15.3: Prevalence and Pathophysiology of Gastro-Esophageal Reflux Disease in Patients with Autoimmune Gastritis. <i>Digestive and Liver Disease</i> , 2017, 49, e121.	0.4	0
392	Vonoprazan fumarate for the management of acid-related diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 1145-1152.	0.9	43
393	Individual Assessment of Gastric Acid Production by Means of a Non-Invasive Test: Relationship between Maximal Acid Output and Pepsinogen I Levels. <i>Gastroenterology</i> , 2017, 152, S471.	0.6	0
394	The added diagnostic value of postreflex swallow-induced peristaltic wave index and nocturnal baseline impedance in refractory reflux disease studied with on-therapy impedance-pH monitoring. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12947.	1.6	107
395	The appropriate use of proton pump inhibitors (PPIs): Need for a reappraisal. <i>European Journal of Internal Medicine</i> , 2017, 37, 19-24.	1.0	184
396	Validation of criteria for the definition of transient lower esophageal sphincter relaxations using high-resolution manometry. <i>Neurogastroenterology and Motility</i> , 2017, 29, e12920.	1.6	78

#	ARTICLE	IF	CITATIONS
397	Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the LÃ©mann Index. <i>Digestive and Liver Disease</i> , 2017, 49, 175-180.	0.4	25
398	Drugs for improving esophageal mucosa defense: where are we now and where are we going?. <i>Annals of Gastroenterology</i> , 2017, 30, 585-591.	0.4	26
399	Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. <i>Annals of Gastroenterology</i> , 2017, 31, 1-7.	0.4	28
400	Update in gastroesophageal reflux disease. <i>Minerva Gastroenterology</i> , 2017, 63, 172-174.	0.3	0
401	Relevance of Measuring Substances in Bronchoalveolar Lavage Fluid for Detecting Aspiration-associated Extraesophageal Reflux Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2017, 23, 318-319.	0.8	1
402	Advances in the physiological assessment and diagnosis of GERD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2017, 14, 665-676.	8.2	157
403	Epidemiology and natural history of gastroesophageal reflux disease. <i>Minerva Gastroenterology</i> , 2017, 63, 175-183.	0.3	30
404	Noncoding RNAs as drivers of the phenotypic plasticity of oesophageal mucosa. <i>World Journal of Gastroenterology</i> , 2017, 23, 7653-7656.	1.4	9
405	Esophageal Motility Testing: The Present and the Future. , 2017, , 201-215.		0
406	The Diagnostic Yield of Novel Parameters in Reflux Monitoring. , 2017, , 217-227.		0
407	Complexity and diversity of gastroesophageal reflux disease phenotypes. <i>Minerva Gastroenterology</i> , 2017, 63, 198-204.	0.3	1
408	Is there a role for high resolution manometry in GERD diagnosis?. <i>Minerva Gastroenterology</i> , 2017, 63, 235-248.	0.3	9
409	A Non-Invasive Serological Test to Assess the Efficacy of Biologic and Non-Biologic Therapies on the Mucosal Health of Patients With Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, S401-S402.	0.2	0
410	Development and Validation of a Multi-marker Serum Test for the Assessment of Mucosal Healing in Crohn's Disease Patients. <i>American Journal of Gastroenterology</i> , 2017, 112, S324.	0.2	1
411	Barrett's esophagus in 2016: From pathophysiology to treatment. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2016, 7, 190.	0.6	18
412	Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis. <i>Journal of Neurogastroenterology and Motility</i> , 2016, 22, 710-711.	0.8	0
413	The impact of bariatric surgery on esophageal function. <i>Annals of the New York Academy of Sciences</i> , 2016, 1381, 98-103.	1.8	24
414	Tricyclic Antidepressants in Refractory GERD: Poorly Effective Drugs or Wrong Patients?. <i>American Journal of Gastroenterology</i> , 2016, 111, 1037-1038.	0.2	1

#	ARTICLE	IF	CITATIONS
415	Vigor of peristalsis during multiple rapid swallows is inversely correlated with acid exposure time in patients with <sc>NERD</sc>. <i>Neurogastroenterology and Motility</i> , 2016, 28, 243-250.	1.6	63
416	Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 1081-1086.	0.6	36
417	P.07.14 BIOLOGICAL THERAPY IS ABLE TO MODIFY THE DISEASE PROGRESSION OF CROHN'S DISEASE PREVENTING ITS LONG-TERM ASSOCIATED DISABILITY – A STUDY PERFORMED USING THE LÅMANN SCORE. <i>Digestive and Liver Disease</i> , 2016, 48, e162-e163.	0.4	1
418	Mo1173 Association Between Eosinophilic Esophagitis and Helicobacter pylori Infection: Preliminary Results of a Multicenter Study. <i>Gastroenterology</i> , 2016, 150, S657-S658.	0.6	1
419	Sa1933 Biological Therapy Is Able to Halt Crohn's Disease Progression: A Prospective, Long Term Study Using the LÅMann Index. <i>Gastroenterology</i> , 2016, 150, S408.	0.6	0
420	P.07.7 CROHN'S DISEASE IS A REAL TIME SENSITIVE EVOLUTIVE PATHOLOGY BASED ON LÅMANN INDEX? PRELIMINARY DATA FROM A TERTIARY PEDIATRIC IBD CENTER. <i>Digestive and Liver Disease</i> , 2016, 48, e160.	0.4	0
421	P.08.5 FEASIBILITY OF HIGH RESOLUTION IMPEDANCE MANOMETRY IN ASSESSING BARRETT'S ESOPHAGUS EXTENSION. <i>Digestive and Liver Disease</i> , 2016, 48, e166-e167.	0.4	0
422	Mo1191 The GerdQ Questionnaire Distinguishes Proton Pump Inhibitor-Responsive Esophageal Eosinophilia From Eosinophilic Esophagitis Patients. <i>Gastroenterology</i> , 2016, 150, S665.	0.6	0
423	In-vivo Axial-strain Sonoelastography Helps Distinguish Acutely-inflamed from Fibrotic Terminal Ileum Strictures in Patients with Crohn's Disease: Preliminary Results. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 855-863.	0.7	32
424	956 Impairment of Chemical Clearance and Mucosal Integrity Distinguish Hypersensitive Esophagus From Functional Heartburn. <i>Gastroenterology</i> , 2016, 150, S189-S190.	0.6	3
425	Tu1975 Factors Predicting Clinical Relapse in Patients With Inflammatory Bowel Diseases During a Long-Term Follow-Up of 5 Years. <i>Gastroenterology</i> , 2016, 150, S995.	0.6	0
426	Tu2009 Does LÅmann Index Reflect the Quality of Life in Crohn Disease Patients on Treatment With Biological Therapy?. <i>Gastroenterology</i> , 2016, 150, S1004-S1005.	0.6	1
427	OC.05.8 ESOPHAGO-GASTRIC JUNCTION MORPHOLOGY VARIABILITY DURING STANDARD MANOMETRIC PROTOCOL AND AFTER ESOPHAGEAL STIMULATION AND BODY CHANGE POSITION – PRELIMINARY RESULTS. <i>Digestive and Liver Disease</i> , 2016, 48, e90.	0.4	0
428	OC.12.1 ARE BASELINE IMPEDANCE LEVELS ASSESSED DURING ESOPHAGEAL IMPEDANCE MANOMETRY HELPFUL IN DISCRIMINATING PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE FROM THOSE WITHOUT? A PILOT STUDY. <i>Digestive and Liver Disease</i> , 2016, 48, e115.	0.4	0
429	P.08.12 GERDQ QUESTIONNAIRE DISTINGUISHES PROTON PUMP INHIBITOR-RESPONSIVE ESOPHAGEAL EOSINOPHILIA FROM EOSINOPHILIC ESOPHAGITIS PATIENTS. <i>Digestive and Liver Disease</i> , 2016, 48, e169.	0.4	0
430	llaprazole for the treatment of gastro-esophageal reflux. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2107-2113.	0.9	13
431	The sensory system of the esophagus – what do we know?. <i>Annals of the New York Academy of Sciences</i> , 2016, 1380, 91-103.	1.8	7
432	Barrett's esophagus detection: Multiple biopsies are useful, even better if you have an – on your map. <i>Digestive and Liver Disease</i> , 2016, 48, 1041-1042.	0.4	1

#	ARTICLE	IF	CITATIONS
433	Interstitial lung disease in systemic sclerosis patients may benefit more from anti-reflux therapies than from immunosuppressants. <i>Autoimmunity Reviews</i> , 2016, 15, 1208-1209.	2.5	10
434	Fecal calprotectin in systemic sclerosis: Light and shade of a promising tool. <i>Autoimmunity Reviews</i> , 2016, 15, 1206-1207.	2.5	2
435	Novel insights into esophageal diagnostic procedures. <i>Annals of the New York Academy of Sciences</i> , 2016, 1380, 162-177.	1.8	5
436	Letter: proton pump inhibitorâ€responsive oesophageal eosinophilia â€ more than just gastroâ€oesophageal reflux disease. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 912-913.	1.9	0
437	Between GERD and NERD: the relevance of weakly acidic reflux. <i>Annals of the New York Academy of Sciences</i> , 2016, 1380, 218-229.	1.8	25
438	Letter: biologics are effective in neutralising the detrimental effect of smoking on the natural course of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 1245-1245.	1.9	2
439	The GerdQ questionnaire and high resolution manometry support the hypothesis that proton pump inhibitorâ€responsive oesophageal eosinophilia is a <scp>GERD</scp>â€related phenomenon. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 522-530.	1.9	38
440	It is Time to Re-Think the Role of Small Intestinal Bacterial Overgrowth in IBS Patients. <i>American Journal of Gastroenterology</i> , 2016, 111, 1364.	0.2	2
441	Functional Heartburn Overlaps With Irritable Bowel Syndrome More Often than GERD. <i>American Journal of Gastroenterology</i> , 2016, 111, 1711-1717.	0.2	55
442	Practice guidelines on the use of esophageal manometry â€ A GISMAD-SIGE-AIGO medical position statement. <i>Digestive and Liver Disease</i> , 2016, 48, 1124-1135.	0.4	82
443	Current treatment options for esophageal diseases. <i>Annals of the New York Academy of Sciences</i> , 2016, 1381, 139-151.	1.8	11
444	Sequential versus standard triple first-line therapy for <i>Helicobacter pylori</i> eradication. <i>The Cochrane Library</i> , 2016, , CD009034.	1.5	35
445	Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1333-1341.	1.5	17
446	The natural history of gastro-esophageal reflux disease: a comprehensive review. <i>Ecological Management and Restoration</i> , 2016, 30, 1-9.	0.2	49
447	173 Esophagogastric Junction Morphology Assessment by High Resolution Manometry and Its Relationship With Gastroesophageal Reflux Disease in Obese Patients Candidate to Bariatric Surgery. <i>Gastroenterology</i> , 2016, 150, S44.	0.6	0
448	Su1081 Which Is the Best Cut-off to Define Ineffective Esophageal Motility?. <i>Gastroenterology</i> , 2016, 150, S463.	0.6	0
449	Tu2007 Inflammatory Bowel Disease And Psychological Status: Determinants And Social Consequences. <i>Gastroenterology</i> , 2016, 150, S1004.	0.6	3
450	PC.01.5 A NEW SUB-CLASSIFICATION OF ESOPHAGO-GASTRIC JUNCTION MORPHOLOGY TYPE I HELPS TO BETTER RECOGNIZE PATIENTS WITH A POSITIVE IMPEDANCE-PH MONITORING. <i>Digestive and Liver Disease</i> , 2016, 48, e69.	0.4	0

#	ARTICLE	IF	CITATIONS
451	OC.02.7 ADALIMUMAB TROUGH LEVELS AT WEEK EIGHT AS PREDICTIVE FACTOR OF LONG TERM CLINICAL REMISSION. <i>Digestive and Liver Disease</i> , 2016, 48, e77-e78.	0.4	0
452	P.08.3 BASELINE IMPEDANCE VALUES CAN REPRESENT A MARKER OF GASTROESOPHAGEAL REFLUX DISEASE AND ARE STRONGLY RELATED WITH THE DURATION OF THE DISEASE. <i>Digestive and Liver Disease</i> , 2016, 48, e165-e166.	0.4	0
453	OC.05.7 LARYNGOPHARYNGEAL SYMPTOMS IN PRIMARY CARE: USEFULNESS OF SALIVARY PEPSIN MEASUREMENT IN PREDICTING GERD. <i>Digestive and Liver Disease</i> , 2016, 48, e89.	0.4	0
454	Are proton pump inhibitors really so dangerous?. <i>Digestive and Liver Disease</i> , 2016, 48, 851-859.	0.4	66
455	Sa1312 Acid is the Key Factor Influencing Esophageal Mean Nocturnal Baseline Impedance but Not Post-reflux Swallow-Induced Peristaltic Wave Index in Gastro-Esophageal Reflux Disease. <i>Gastroenterology</i> , 2016, 150, S278-S279.	0.6	0
456	OC.07.1 REFRACTORY PATIENTS WITH NON-ACID REFLUX DISEASE AND THOSE WITH EROSIIVE AND NON-EROSIVE REFLUX DISEASE HAVE SIMILAR RESPONSE TO ANTI-REFLUX SURGICAL THERAPY. <i>Digestive and Liver Disease</i> , 2016, 48, e95.	0.4	0
457	The contribution of intraepithelial inflammatory cells to the histological diagnosis of microscopic esophagitis. <i>Esophagus</i> , 2016, 13, 80-87.	1.0	7
458	Sa1268 Feasibility of High Resolution Impedance Manometry in Assessing Barrett's Esophagus Extension. <i>Gastroenterology</i> , 2016, 150, S263-S264.	0.6	0
459	Sa1296 A Sub-classification of Esophago-Gastric Junction Morphology Type I May Be Useful To Better Recognize GERD Patients With a Positive Impedance-pH Monitoring. <i>Gastroenterology</i> , 2016, 150, S273.	0.6	0
460	P.07.15 INFlixIMAB TROUGH LEVELS AND ANTI-DRUG ANTIBODIES AFTER INDUCTION AS PREDICTIVE FACTORS OF LONG TERM CLINICAL REMISSION. <i>Digestive and Liver Disease</i> , 2016, 48, e163.	0.4	0
461	OC.02.6 IDENTIFICATION OF A CUT-OFF FOR PERSISTENT ANTI-INFlixIMAB ANTIBODIES AS A PREDICTOR OF RESPONSE TO INFlixIMAB MONOTHERAPY. <i>Digestive and Liver Disease</i> , 2016, 48, e77.	0.4	0
462	P.08.10 ESOPHAGOGASTRIC JUNCTION MORPHOLOGY ASSESSMENT BY HIGH RESOLUTION MANOMETRY IN OBESE PATIENTS CANDIDATE TO BARIATRIC SURGERY. <i>Digestive and Liver Disease</i> , 2016, 48, e168.	0.4	0
463	Lower pH values of weakly acidic refluxes as determinants of heartburn perception in gastroesophageal reflux disease patients with normal esophageal acid exposure. <i>Ecological Management and Restoration</i> , 2016, 29, 3-9.	0.2	15
464	Voluntary and controlled weight loss can reduce symptoms and proton pump inhibitor use and dosage in patients with gastroesophageal reflux disease: a comparative study. <i>Ecological Management and Restoration</i> , 2016, 29, 197-204.	0.2	49
465	Caution About Overinterpretation of Number of Reflux Episodes in Reflux Monitoring for Refractory Gastroesophageal Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1060.	2.4	3
466	Analyses of the Post-reflux Swallow-induced Peristaltic Wave Index and Nocturnal Baseline Impedance Parameters Increase the Diagnostic Yield of Impedance-pH Monitoring of Patients With Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 40-46.	2.4	222
467	The Impact of Heller Myotomy on Integrated Relaxation Pressure in Esophageal Achalasia. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 125-131.	0.9	20
468	P.08.16 NEW IMPEDANCE-PH PARAMETERS OF GASTRO-ESOPHAGEAL REFLUX DISEASE: A LESSON FROM PATIENTS WITH CHRONIC AUTOIMMUNE ATROPHIC GASTRITIS, NON-EROSIVE REFLUX DISEASE AND FUNCTIONAL HEARTBURN. <i>Digestive and Liver Disease</i> , 2016, 48, e171.	0.4	0

#	ARTICLE	IF	CITATIONS
469	High-resolution Impedance Manometry after Sleeve Gastrectomy: Increased Intra-gastric Pressure and Reflux are Frequent Events. <i>Obesity Surgery</i> , 2016, 26, 2449-2456.	1.1	124
470	Esophagogastric junction morphology assessment by high resolution manometry in obese patients candidate to bariatric surgery. <i>International Journal of Surgery</i> , 2016, 28, S109-S113.	1.1	21
471	Comparison of computed tomography and magnetic resonance imaging in the discrimination of intraperitoneal and extraperitoneal rectal cancer: initial experience. <i>Clinical Imaging</i> , 2016, 40, 57-62.	0.8	3
472	Effects of omega-loop bypass on esophagogastric junction function. <i>Surgery for Obesity and Related Diseases</i> , 2016, 12, 62-69.	1.0	117
473	Pre-operative clinical and instrumental factors as antireflux surgery outcome predictors. <i>World Journal of Gastrointestinal Surgery</i> , 2016, 8, 719.	0.8	9
474	Esophageal testing: What we have so far. <i>World Journal of Gastrointestinal Pathophysiology</i> , 2016, 7, 72.	0.5	26
475	Clinical, endoscopic, histological and radiological characteristics of Italian patients with eosinophilic oesophagitis. <i>Digestive and Liver Disease</i> , 2015, 47, 1033-1038.	0.4	10
476	Normal values of esophageal motility after antireflux surgery; a study using high-resolution manometry. <i>Neurogastroenterology and Motility</i> , 2015, 27, 929-935.	1.6	37
477	Esophagogastric junction morphology is associated with a positive impedance-pH monitoring in patients with GERD. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1175-1182.	1.6	91
478	Esophagogastric junction contractility for clinical assessment in patients with GERD: a real added value?. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1423-1431.	1.6	85
479	Impedance-detected Symptom Association and Number of Reflux Episodes as Pre-treatment Parameters That Predict Outcomes of Gastroesophageal Reflux Disease Patients. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 292-293.	0.8	2
480	A More In-depth Evaluation of Impedance-pH Could Assist in Distinguishing Reflux-related From Reflux-unrelated Heartburn. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 621-622.	0.8	1
481	Optimal management of constipation associated with irritable bowel syndrome. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 691.	0.9	11
482	Radiofrequency Catheter Ablation for Atrial Fibrillation Elicited "Jackhammer Esophagus": A New Complication Due to Vagal Nerve Stimulation?. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 612-615.	0.8	16
483	Weight Loss Is Truly Effective in Reducing Symptoms and Proton Pump Inhibitor Use in Patients With Gastroesophageal Reflux Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 2023.	2.4	5
484	Anti-Tumor Necrosis Factor Antibodies for Prevention of Crohn's Disease Recurrence After Surgery: More Than a Hope. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1856.	2.4	1
485	Association Between Baseline Impedance Values and Response Proton Pump Inhibitors in Patients With Heartburn. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1082-1088.e1.	2.4	121
486	Measurement of oro-caecal transit time by magnetic resonance imaging. <i>European Radiology</i> , 2015, 25, 1579-1587.	2.3	13

#	ARTICLE	IF	CITATIONS
487	Incidental physiological sliding hiatal hernia: a single center comparison study between CT with water enema and CT colonography. <i>Radiologia Medica</i> , 2015, 120, 683-689.	4.7	3
488	Adalimumab Trough Levels and Response to Biological Treatment in Patients With Inflammatory Bowel Disease: A Useful Cutoff in Clinical Practice. <i>American Journal of Gastroenterology</i> , 2015, 110, 472-473.	0.2	6
489	Mo1128 Are Baseline Impedance Levels Assessed During Esophageal Impedance Manometry Helpful in Discriminating Patients With Gastroesophageal Reflux Disease From Those Without? A Pilot Study. <i>Gastroenterology</i> , 2015, 148, S-614-S-615.	0.6	0
490	Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring. <i>Digestive and Liver Disease</i> , 2015, 47, 1027-1032.	0.4	12
491	Data on Symptom Association Analysis in Patients Undergoing Endoscopic Therapy Is Useful to Better Define a Successful Therapeutic Approach. <i>American Journal of Gastroenterology</i> , 2015, 110, 1621.	0.2	2
492	The Chicago Classification of esophageal motility disorders, v3.0. <i>Neurogastroenterology and Motility</i> , 2015, 27, 160-174.	1.6	1,628
493	Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2014, 20, 129-130.	0.8	2
494	Esophageal motility abnormalities in gastroesophageal reflux disease. <i>World Journal of Gastrointestinal Pharmacology and Therapeutics</i> , 2014, 5, 86.	0.6	68
495	Light microscopy is useful to better define NERD and functional heartburn. <i>Gut</i> , 2014, 63, 368-368.	6.1	6
496	Arterial congestive gastropathy: a new entity?. <i>Endoscopy</i> , 2014, 46, E397-E398.	1.0	0
497	Esophageal biopsies in the management of GERD: complementary tool for many but not for all. <i>Human Pathology</i> , 2014, 45, 2512-2513.	1.1	3
498	Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?. <i>Neurogastroenterology and Motility</i> , 2014, 26, 28-35.	1.6	73
499	Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. <i>Neurogastroenterology and Motility</i> , 2014, 26, 546-555.	1.6	185
500	Letter: treatment for small intestinal bacterial overgrowth " where are we now?. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 442-442.	1.9	2
501	Letter: biological therapies are effective for prevention of postoperative Crohn's disease recurrence. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 322-322.	1.9	3
502	P.10.21 PATIENTS WITH NEGATIVE IMPEDANCE AND PH WHO RESPOND TO ACID SUPPRESSION: ARE THEY HYPERSENSITIVE PATIENTS? A STUDY WITH BASELINE IMPEDANCE VALUES AND PSPW INDEX. <i>Digestive and Liver Disease</i> , 2014, 46, S91-S92.	0.4	0
503	P.13.17 INTRA- AND INTEROBSERVER AGREEMENT BETWEEN ENDOSCOPISTS AND PATHOLOGISTS FOR DETECTION OF GASTRIC INTESTINAL METAPLASIA BY MEANS OF NARROW BAND IMAGING WITH MAGNIFYING ENDOSCOPY. <i>Digestive and Liver Disease</i> , 2014, 46, S106.	0.4	0
504	P.10.22 EVALUATION OF SLEEP DISRUPTIONS BY MEANS OF IMPEDANCE-PH MONITORING IN PATIENTS WITH NERD. <i>Digestive and Liver Disease</i> , 2014, 46, S92.	0.4	0

#	ARTICLE	IF	CITATIONS
505	OC.02.2 REFLUX PATTERN AND ROLE OF IMPEDANCE-PH VARIABLES IN PREDICTING PPI RESPONSE IN PATIENTS WITH SUSPECTED GERD-RELATED CHRONIC COUGH. <i>Digestive and Liver Disease</i> , 2014, 46, S7.	0.4	1
506	OC.02.5 DIFFERENT ACCURACY OF VARIOUS IMPEDANCE-PH NORMAL VALUES IN DIAGNOSING GERD IN PATIENTS WITH PROVEN OR HIGHLY SUSPECTED REFLUX DISEASE. <i>Digestive and Liver Disease</i> , 2014, 46, S8.	0.4	3
507	PC.01.1 COMPARISON BETWEEN SOLID-STATE AND WATER-PERFUSED SYSTEM FOR THE DIAGNOSIS OF PRIMARY ESOPHAGEAL MOTILITY DISORDERS. <i>Digestive and Liver Disease</i> , 2014, 46, S1.	0.4	0
508	P505 ELISA vs. HMSA: a comparison between two different methods for the evaluation of adalimumab serum concentration and anti-adalimumab antibodies – Preliminary data. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S278.	0.6	2
509	P656 Fcγ3 Receptor Type IIIa polymorphisms and their correlation with clinical outcome in patients with inflammatory bowel disease during a long term follow up. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S344.	0.6	0
510	Symptom analysis improves GERD diagnosis and may be helpful to define a successful surgical approach. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014, 28, 698-699.	1.3	1
511	Not all anti-reflux treatment failures are due to persistence of abnormal esophageal acid exposure. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014, 28, 1382-1383.	1.3	1
512	EAES recommendations for the management of gastroesophageal reflux disease. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2014, 28, 1753-1773.	1.3	194
513	Reflux pattern and role of impedance-pH variables in predicting PPI response in patients with suspected GERD-related chronic cough. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 40, 966-973.	1.9	63
514	Comment on – Impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis – by Marzio Frazzoni et al. [ <i>Digestive and Liver Disease</i> 2014;46:596-602]. <i>Digestive and Liver Disease</i> , 2014, 46, 1052.	0.4	0
515	Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab. <i>Digestive and Liver Disease</i> , 2014, 46, 1043-1046.	0.4	17
516	Gastrointestinal involvement in systemic sclerosis. <i>Presse Medicale</i> , 2014, 43, e279-e291.	0.8	59
517	The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders. <i>Journal of Gastroenterology</i> , 2014, 49, 1362-1363.	2.3	1
518	An Unusual Cutaneous Manifestation in a Patient With Cystic Fibrosis. <i>Gastroenterology</i> , 2014, 147, e10-e11.	0.6	2
519	P.10.26 DISTAL AND PROXIMAL ESOPHAGEAL IMPEDANCE BASAL VALUES IN PATIENTS WITH NON-EROSIVE REFLUX DISEASE AND FUNCTIONAL HEARTBURN. <i>Digestive and Liver Disease</i> , 2014, 46, S93.	0.4	1
520	OC.14.2 ASSESSMENT OF TOLERABILITY, DURATION AND COSTS OF SOLID-STATE AND WATER-PERFUSED SYSTEM DURING ESOPHAGEAL MOTILITY TESTING. <i>Digestive and Liver Disease</i> , 2014, 46, S32.	0.4	0
521	P.10.19 DIFFERENT IMPEDANCE-PH REFLUX PATTERNS IN SYMPTOMATIC CHOLECISTECTOMIZED AND NON-CHOLECISTECTOMIZED PATIENTS. <i>Digestive and Liver Disease</i> , 2014, 46, S91.	0.4	0
522	OC.18.4 CLINICAL AND ENDOSCOPIC CHARACTERISTICS OF PATIENTS WITH EOSINOPHILIC ESOPHAGITIS – DATA FROM A SINGLE TERTIARY ITALIAN CENTER. <i>Digestive and Liver Disease</i> , 2014, 46, S39-S40.	0.4	0

#	ARTICLE	IF	CITATIONS
523	Ultrasound-guided procedures around the wrist and hand: How to do. <i>European Journal of Radiology</i> , 2014, 83, 1231-1238.	1.2	38
524	DOP057 The influence of anti-adalimumab antibodies on adalimumab trough levels, TNF- $\hat{\pm}$ levels and clinical outcome. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S42.	0.6	3
525	Prevention of Crohn's Disease Recurrence After Surgery: On the Road to Recovery. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1406.	2.4	0
526	Granulo-monocyto apheresis is more effective in mild ulcerative colitis than in moderate to severe disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 17155.	1.4	6
527	Eosinophilic oesophagitis: From physiopathology to treatment. <i>Digestive and Liver Disease</i> , 2013, 45, 871-878.	0.4	25
528	The pharmacokinetics of ilaprazole for gastro-esophageal reflux treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1361-1369.	1.5	30
529	The importance of subgrouping refractory NERD patients according to esophageal pH-impedance testing. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2013, 27, 3503-3504.	1.3	0
530	Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. <i>Journal of Gastroenterology</i> , 2013, 48, 473-482.	2.3	157
531	Esophageal acid exposure still plays a major role in patients with NERD. <i>Journal of Gastroenterology</i> , 2013, 48, 552-553.	2.3	1
532	Ultrasound-guided core-needle biopsy of extra-ocular orbital lesions. <i>European Radiology</i> , 2013, 23, 1919-1924.	2.3	46
533	Non-erosive reflux disease patients are more complex than the sole endoscopy tells us. <i>Clinical Oral Investigations</i> , 2013, 17, 1965-1966.	1.4	0
534	Symptom association analysis is important in GERD patients undergoing endoscopic therapy. <i>Gastrointestinal Endoscopy</i> , 2013, 77, 832.	0.5	0
535	Comment to "Predictors of clinical response of acid suppression in Chinese patients with gastroesophageal reflux disease"; <i>Digestive and Liver Disease</i> , 2013, 45, 868-869.	0.4	1
536	RE: A Simple Technique to Restore Needle Patency During Percutaneous Lavage and Aspiration of Calcific Rotator Cuff Tendinopathy. <i>PM and R</i> , 2013, 5, 633-633.	0.9	11
537	Functional testing: pharyngeal pH monitoring and high-resolution manometry. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 226-235.	1.8	12
538	Defining esophageal landmarks, gastroesophageal reflux disease, and Barrett's esophagus. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 278-295.	1.8	17
539	Tu1805 Different Accuracy of Various Impedance-pH Normal Values in Diagnosing GERD in Patients With Proven Reflux Disease. <i>Gastroenterology</i> , 2013, 144, S-850-S-851.	0.6	0
540	Tu1771 Impedance-pH Explores With More Accuracy Than pH-Metry Alone the Relationship Between Aspiration of Gastric Contents and Gastroesophageal Reflux in Patients With Idiopathic Pulmonary Fibrosis. <i>Gastroenterology</i> , 2013, 144, S-840-S-841.	0.6	0

#	ARTICLE	IF	CITATIONS
541	OC.06.1 USE OF A NON-INVASIVE PEPSIN DIAGNOSTIC TEST TO DETECT GERD: CORRELATION WITH MII-pH EVALUATION IN A SERIES OF SUSPECTED NERD PATIENTS. A PILOT STUDY. <i>Digestive and Liver Disease</i> , 2013, 45, S68-S69.	0.4	3
542	Narrow-band imaging with magnifying endoscopy is accurate for detecting gastric intestinal metaplasia. <i>World Journal of Gastroenterology</i> , 2013, 19, 2668.	1.4	35
543	NERD: an umbrella term including heterogeneous subpopulations. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 371-380.	8.2	184
544	Lactulose Breath Test to Assess Oro-cecal Transit Delay and Estimate Esophageal Dysmotility in Scleroderma Patients. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 42, 522-529.	1.6	29
545	Endotherapy for and tailored approaches to treating GERD, and refractory GERD. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 166-186.	1.8	9
546	Dysmotility and reflux disease. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2013, 21, 1.	0.8	21
547	Optimal treatment of laryngopharyngeal reflux disease. <i>Therapeutic Advances in Chronic Disease</i> , 2013, 4, 287-301.	1.1	70
548	Letter: symptom indexes in reflux monitoring –two are better than one. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 918-918.	1.9	1
549	Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial. <i>American Journal of Gastroenterology</i> , 2013, 108, 1731-1742.	0.2	187
550	Innovative techniques in evaluating the esophagus; imaging of esophageal morphology and function; and drugs for esophageal disease. <i>Annals of the New York Academy of Sciences</i> , 2013, 1300, 11-28.	1.8	6
551	Gastrointestinal motility disorder assessment in systemic sclerosis. <i>Rheumatology</i> , 2013, 52, 1095-1100.	0.9	87
552	Non-Erosive Reflux Disease is More Complex Than Negative Endoscopy Only. <i>American Journal of Gastroenterology</i> , 2013, 108, 1657-1658.	0.2	0
553	Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. <i>European Respiratory Journal</i> , 2013, 42, 1322-1331.	3.1	194
554	Nonerosive reflux disease and functional heartburn are clearly separate entities. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 749-750.	0.8	2
555	A Comparison Between Lactose Breath Test and Quick Test on Duodenal Biopsies for Diagnosing Lactase Deficiency in Patients With Self-reported Lactose Intolerance. <i>Journal of Clinical Gastroenterology</i> , 2013, 47, 148-152.	1.1	29
556	Therapeutic potential of curcumin in digestive diseases. <i>World Journal of Gastroenterology</i> , 2013, 19, 9256.	1.4	103
557	Noninfectious interstitial lung disease during infliximab therapy: Case report and literature review. <i>World Journal of Gastroenterology</i> , 2013, 19, 5377.	1.4	16
558	Overlap of functional heartburn and gastroesophageal reflux disease with irritable bowel syndrome. <i>World Journal of Gastroenterology</i> , 2013, 19, 5787.	1.4	46

#	ARTICLE	IF	CITATIONS
559	Studies on factors predicting GORD response to proton-pump inhibitors: NERD subpopulations need to be analysed separately. <i>Gut</i> , 2012, 61, 1368.2-1369.	6.1	0
560	The relevance of symptom association analysis in GORD patients undergoing anti-reflux surgery. <i>Gut</i> , 2012, 61, 326.1-326.	6.1	1
561	Adalimumab for the prevention of recurrence after surgery for Crohn's disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2012, 24, 863-864.	0.8	23
562	Alginate controls heartburn in patients with erosive and nonerosive reflux disease. <i>World Journal of Gastroenterology</i> , 2012, 18, 4371.	1.4	59
563	It is time to plan clinical trials on true NERD patients. <i>Neurogastroenterology and Motility</i> , 2012, 24, 885-886.	1.6	1
564	Ultrasound Assessment of the Rotator Cuff Cable: Comparison Between Young and Elderly Asymptomatic Volunteers and Interobserver Reproducibility. <i>Ultrasound in Medicine and Biology</i> , 2012, 38, 35-41.	0.7	14
565	The Relevance of Weakly Acidic Reflux in Patients With Barrett's Esophagus. <i>Gastroenterology</i> , 2012, 143, e21-e22.	0.6	2
566	Functional aspects of distal oesophageal spasm: The role of onset velocity and contraction amplitude on bolus transit. <i>Digestive and Liver Disease</i> , 2012, 44, 569-575.	0.4	4
567	Impedance-pH reflux patterns can differentiate non-erosive reflux disease from functional heartburn patients. <i>Journal of Gastroenterology</i> , 2012, 47, 159-168.	2.3	102
568	How many cases of laryngopharyngeal reflux suspected by laryngoscopy are gastroesophageal reflux disease-related?. <i>World Journal of Gastroenterology</i> , 2012, 18, 4363.	1.4	132
569	Achalasia With Dense Eosinophilic Infiltrate Responds to Steroid Therapy. <i>Clinical Gastroenterology and Hepatology</i> , 2011, 9, 1104-1106.	2.4	62
570	Gastroesophageal Reflux is More Relevant Than Motor Dysfunction in Provoking Non-Cardiac Chest Pain. <i>Gastroenterology</i> , 2011, 140, S-251-S-252.	0.6	0
571	OC.03.5: REFLUX PATTERNS DIFFER AMONG PATIENTS WITH NON-EROSIVE REFLUX DISEASE (NERD), HYPERSENSITIVE ESOPHAGUS (HE) AND FUNCTIONAL HEARTBURN (FH). <i>Digestive and Liver Disease</i> , 2011, 43, S124-S125.	0.4	0
572	OC.03.6: PREVALENCE OF ESOPHAGEAL MOTILITY ABNORMALITIES IN PATIENTS WITH NON-EROSIVE REFLUX DISEASE, EROSIVE ESOPHAGITIS, BARRETT ESOPHAGUS AND FUNCTIONAL HEARTBURN. <i>Digestive and Liver Disease</i> , 2011, 43, S125.	0.4	0
573	P.1.37: GASTROESOPHAGEAL REFLUX IS MORE RELEVANT THAN ESOPHAGEAL MOTOR DYSFUNCTION IN PROVOKING NON-CARDIAC CHEST PAIN IN ENDOSCOPY-NEGATIVE PATIENTS. <i>Digestive and Liver Disease</i> , 2011, 43, S160.	0.4	0
574	P.1.44: PREVALENCE OF NON-POLYPOID LATERALLY SPREADING TUMORS (LST) AND ROLE OF MUCOSECTOMY IN THEIR REMOVAL: OUR EXPERIENCE. <i>Digestive and Liver Disease</i> , 2011, 43, S163.	0.4	0
575	P.1.69: PREVALENCE OF SERRATED ADENOMAS IN PATIENTS WHO UNDERWENT PAN-COLONOSCOPY: A RETROSPECTIVE STUDY. <i>Digestive and Liver Disease</i> , 2011, 43, S171.	0.4	0
576	P.1.106: DIFFERENCES IN REFLUX CHARACTERISTICS CAN BE DIAGNOSTIC IN NERD PATIENTS WHEN SYMPTOMS DO NOT OCCUR DURING MII-PH TESTING. <i>Digestive and Liver Disease</i> , 2011, 43, S183.	0.4	0

#	ARTICLE	IF	CITATIONS
577	P.1.201: CAN WE ESTIMATE ORO-CECAL TRANSIT TIME USING MRI? A COMPARISON WITH HYDROGEN BREATH TEST (H2-BT) IN HEALTHY VOLUNTEERS. <i>Digestive and Liver Disease</i> , 2011, 43, S214-S215.	0.4	0
578	The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. <i>Digestive and Liver Disease</i> , 2011, 43, 542-547.	0.4	140
579	Comment to "Current applications of evolving methodologies in gastroesophageal reflux disease testing" <i>Digestive and Liver Disease</i> , 2011, 43, 835.	0.4	0
580	Nocturnal reflux and sleep disturbances: An overlooked link in the past. <i>Digestive and Liver Disease</i> , 2011, 43, 755-756.	0.4	1
581	Overweight is a risk factor for both erosive and non-erosive reflux disease. <i>Digestive and Liver Disease</i> , 2011, 43, 940-945.	0.4	52
582	Impedance-pH Monitoring Increases the Diagnostic Yield in Endoscopic Negative Patients With Non-Cardiac Chest Pain. <i>Gastroenterology</i> , 2011, 140, S-247-S-248.	0.6	0
583	The Differing Role of Overweight Among the Various Subgroups of Non-Erosive Reflux Disease. <i>Gastroenterology</i> , 2011, 140, S-627.	0.6	0
584	Can We Estimate Oro-Cecal Transit Time Using Magnetic Resonance Imaging (MRI)? A Comparison With Hydrogen Breath Test (H2-BT) in Healthy Volunteers. <i>Gastroenterology</i> , 2011, 140, S-446.	0.6	0
585	P.1.253: METHANE PRODUCTION ASSESSED BY GLUCOSE BREATH TEST IS ASSOCIATED WITH FUNCTIONAL CONSTIPATION HABIT. <i>Digestive and Liver Disease</i> , 2011, 43, S232.	0.4	0
586	Microscopic esophagitis and Barrett's esophagus: The histology report. <i>Digestive and Liver Disease</i> , 2011, 43, S319-S330.	0.4	33
587	Prevention of postoperative recurrence of Crohn's disease by Adalimumab. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 24, 1.	0.8	21
588	Oesophageal motility and bolus transit abnormalities increase in parallel with the severity of gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 476-486.	1.9	172
589	The reason for failure of on-demand PPI therapy in NERD patients. <i>Neurogastroenterology and Motility</i> , 2011, 23, 811-811.	1.6	1
590	Barrett's esophagus: proton pump inhibitors and chemoprevention II. <i>Annals of the New York Academy of Sciences</i> , 2011, 1232, 114-139.	1.8	12
591	Barrett's esophagus: surgical treatments. <i>Annals of the New York Academy of Sciences</i> , 2011, 1232, 175-195.	1.8	4
592	Ultrasound-guided percutaneous injection of triamcinolone acetonide for treating capsular contracture in patients with augmented and reconstructed breast. <i>European Radiology</i> , 2011, 21, 575-581.	2.3	16
593	The Role of Acid in Functional Dyspepsia. <i>American Journal of Gastroenterology</i> , 2011, 106, 1168.	0.2	9
594	The Relevance of Reflux Monitoring Off Therapy. <i>American Journal of Gastroenterology</i> , 2011, 106, 1558-1559.	0.2	0

#	ARTICLE	IF	CITATIONS
595	Small Intestinal Bacterial Overgrowth and Helicobacter pylori : Can They Be Cause of Thrombocytopenia in Patients With Chronic Liver Disease?. American Journal of Gastroenterology, 2011, 106, 1171-1172.	0.2	3
596	Emerging Factors of Survival in Usual Interstitial Pneumonia and Nonspecific Interstitial Pneumonia. Chest, 2010, 138, 534A.	0.4	0
597	Clinical trial: the combination of rifaximin with partially hydrolysed guar gum is more effective than rifaximin alone in eradicating small intestinal bacterial overgrowth. Alimentary Pharmacology and Therapeutics, 2010, 32, 1000-1006.	1.9	62
598	Characteristics of gastro-esophageal reflux episodes in Barrett's esophagus, erosive esophagitis and healthy volunteers. Neurogastroenterology and Motility, 2010, 22, 1061-e280.	1.6	72
599	Characteristics of Reflux Episodes and Symptom Association in Patients With Erosive Esophagitis and Nonerosive Reflux Disease: Study Using Combined Impedance-pH Off Therapy. American Journal of Gastroenterology, 2010, 105, 1053-1061.	0.2	190
600	Excellent agreement between genetic and hydrogen breath tests for lactase deficiency and the role of extended symptom assessment. British Journal of Nutrition, 2010, 104, 900-907.	1.2	55
601	OC.08.2 MICROSCOPIC ESOPHAGITIS IS MORE FREQUENT IN PATIENTS WITH PH-POSITIVE NON-EROSIVE REFLUX DISEASE AND HYPERSENSITIVE ESOPHAGUS THAN IN THOSE WITH FUNCTIONAL HEARTBURN: A STUDY USING IMPEDANCE-pH AND OPTICAL MICROSCOPY. Digestive and Liver Disease, 2010, 42, S89.	0.4	0
602	P.11 IS NONACID ACIDIC REFLUX INCREASED IN CHOLECYSTECTOMIZED PATIENTS WITH TYPICAL REFLUX SYMPTOMS? A STUDY USING IMPEDANCE-pH MONITORING. Digestive and Liver Disease, 2010, 42, S106.	0.4	0
603	P.14 PREVALENCE OF ESOPHAGEAL MOTILITY ABNORMALITIES IN PATIENTS WITH TRUE NON-EROSIVE REFLUX DISEASE, EROSIVE ESOPHAGITIS, BARRETT ESOPHAGUS AND FUNCTIONAL HEARTBURN. Digestive and Liver Disease, 2010, 42, S107.	0.4	0
604	P.18 SYMPTOM ASSOCIATION PROBABILITY FOR ACID AND NONACID REFLUX IN PATIENTS WITH EROSIVE ESOPHAGITIS (EE) AND NON-EROSIVE REFLUX DISEASE (NERD). Digestive and Liver Disease, 2010, 42, S109.	0.4	0
605	P.49 ULTRASOUND EVALUATION OF THE POSTERIOR COMPARTMENT OF THE FEMALE PELVIC FLOOR: TRANS-LABIAL ASSESSMENT OF NORMAL ANATOMY AND PATHOLOGIC CONDITIONS. Digestive and Liver Disease, 2010, 42, S120-S121.	0.4	0
606	Functional heartburn has more in common with functional dyspepsia than with non-erosive reflux disease. Gut, 2009, 58, 1185-1191.	6.1	206
607	Gastroesophageal Reflux and Pulmonary Fibrosis in Scleroderma. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 408-413.	2.5	251
608	Microscopic esophagitis in gastro-esophageal reflux disease: individual lesions, biopsy sampling, and clinical correlations. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2009, 454, 31-39.	1.4	42
609	Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy. Alimentary Pharmacology and Therapeutics, 2009, 30, 508-515.	1.9	53
610	LACTULOSE BREATH TEST IS A NON-INVASIVE TOOL TO ASSESS ESOPHAGEAL INVOLVEMENT IN SCLERODERMA PATIENTS. Digestive and Liver Disease, 2009, 41, S44.	0.4	0
611	NONACID REFLUX IS ABLE TO DETERMINE MICROSCOPIC ESOPHAGITIS IN NON-EROSIVE REFLUX DISEASE (NERD) PATIENTS. Digestive and Liver Disease, 2009, 41, S64.	0.4	0
612	REFLUX AND DYSPEPTIC SYMPTOM PATTERNS IN PATIENTS WITH NON-EROSIVE REFLUX DISEASE (NERD) SUBCLASSIFIED USING 24-HOUR AMBULATORY INTRALUMINAL pH-IMPEDANCE. Digestive and Liver Disease, 2009, 41, S65.	0.4	0

#	ARTICLE	IF	CITATIONS
613	DEMOGRAPHIC AND CLINICAL FEATURES HELP TO IDENTIFY NON EROSIIVE REFLUX DISEASE (NERD) PATIENTS WITH ABNORMAL pH-IMPEDANCE TESTING. <i>Digestive and Liver Disease</i> , 2009, 41, S77.	0.4	0
614	GASTROINTESTINAL ASSESSMENT IN A LARGE COHORT OF PATIENTS SUFFERING FROM SYSTEMIC SCLEROSIS. <i>Digestive and Liver Disease</i> , 2009, 41, S140-S141.	0.4	0
615	Proton pump inhibitors in GORDAn overview of their pharmacology, efficacy and safety. <i>Pharmacological Research</i> , 2009, 59, 135-153.	3.1	156
616	Positive Glucose Breath Testing is More Prevalent in Patients With IBS-like Symptoms Compared With Controls of Similar Age and Gender Distribution. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 962-966.	1.1	59
617	Gastroesophageal Reflux and Lung Disease in Systemic Sclerosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 1167-1168.	2.5	1
618	The Italian validation of the Montreal Global definition and classification of gastroesophageal reflux disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 394-408.	0.8	14
619	PA.3 PREVALENCE OF DYSPEPSIA SYMPTOMS IN PATIENTS WITH NON EROSIIVE REFLUX DISEASE (NERD) SUBCLASSIFIED USING 24-HOUR AMBULATORY INTRALUMINAL PH-IMPEDANCE. <i>Digestive and Liver Disease</i> , 2008, 40, S76-S77.	0.4	0
620	PA.132 FINDINGS AFTER ULTRASOUND-GUIDED FINE NEEDLE AGO-BIOPSY (FNAB) IN SUSPECTED PANCREATIC LESIONS. <i>Digestive and Liver Disease</i> , 2008, 40, S123.	0.4	0
621	PA.181 PREDICTABLE BOLUS RETENTION SITE ALONG THE ESOPHAGUS IN PATIENTS WITH ESOPHAGEAL SYMPTOMS: STUDIES USING COMBINED IMPEDANCE-MANOMETRY TESTING. <i>Digestive and Liver Disease</i> , 2008, 40, S142.	0.4	0
622	PA.243 CONVENTIONAL CONTRAST-ENHANCED ULTRASONOGRAPHY (CEUS) VERSUS SIDE-BY-SIDE CEUS IN THE ASSESSMENT OF "DIFFICULT" LIVER LESIONS. <i>Digestive and Liver Disease</i> , 2008, 40, S164.	0.4	0
623	Combined multichannel intraluminal impedance and manometry testing. <i>Digestive and Liver Disease</i> , 2008, 40, 167-173.	0.4	30
624	Small Intestinal Bacterial Overgrowth in Rosacea: Clinical Effectiveness of Its Eradication. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 759-764.	2.4	177
625	Management Strategy for Patients With Gastroesophageal Reflux Disease: A Comparison Between Empirical Treatment With Esomeprazole and Endoscopy-Oriented Treatment. <i>American Journal of Gastroenterology</i> , 2008, 103, 267-275.	0.2	60
626	The Role of Nonacid Reflux in NERD: Lessons Learned From Impedance-pH Monitoring in 150 Patients off Therapy. <i>American Journal of Gastroenterology</i> , 2008, 103, 2685-2693.	0.2	224
627	Small Intestinal Bacterial Overgrowth in Patients Suffering From Scleroderma: Clinical Effectiveness of Its Eradication. <i>American Journal of Gastroenterology</i> , 2008, 103, 1257-1262.	0.2	114
628	Characteristics of the Esophageal Low-Pressure Zone in Healthy Volunteers and Patients With Esophageal Symptoms: Assessment by High-Resolution Manometry. <i>American Journal of Gastroenterology</i> , 2008, 103, 2544-2549.	0.2	41
629	Is acid relevant in the genesis of dyspeptic symptoms associated with nonerosive reflux disease?. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 252-254.	0.8	3
630	Functional Heartburn and Non-Erosive Reflux Disease. <i>Digestive Diseases</i> , 2007, 25, 172-174.	0.8	49

#	ARTICLE	IF	CITATIONS
631	Evidence of Prolonged Orocecal Transit Time and Small Intestinal Bacterial Overgrowth in Acromegalic Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2119-2124.	1.8	40
632	Normal values of 24-h ambulatory intraluminal impedance combined with pH-metry in subjects eating a Mediterranean diet. <i>Digestive and Liver Disease</i> , 2006, 38, 226-232.	0.4	139
633	Pharmacodynamic studies on PPIs: Look carefully at the country of origin. <i>Digestive and Liver Disease</i> , 2006, 38, 808-810.	0.4	1
634	Can Helicobacter pylori Eradication Regimens be Shortened in Clinical Practice? An Open-label, Randomized, Pilot Study of 4 and 7-day Triple Therapy With Rabeprazole, High-dose Levofloxacin, and Tinidazole. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 515-520.	1.1	16
635	A Comparison Between Sodium Alginate and Magaldrate Anhydrous in the Treatment of Patients with Gastroesophageal Reflux Symptoms. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1904-1909.	1.1	31
636	Role of partially hydrolyzed guar gum in the treatment of irritable bowel syndrome. <i>Nutrition</i> , 2006, 22, 334-342.	1.1	96
637	Proton Pump Inhibitor Failure: Why Does It Occur and How Can It Be Managed?. <i>Digestion</i> , 2006, 73, 215-217.	1.2	11
638	An evaluation of the antireflux properties of sodium alginate by means of combined multichannel intraluminal impedance and pH-metry. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 29-34.	1.9	74
639	Helicobacter pylori and tolerance to H2-blockers. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 289-290.	1.9	2
640	Air swallowing can be responsible for non-response of heartburn to high-dose proton pump inhibitor. <i>Digestive and Liver Disease</i> , 2005, 37, 454-457.	0.4	4
641	Reassessment of the Diagnostic Value of Histology in Patients with GERD, Using Multiple Biopsy Sites and an Appropriate Control Group. <i>American Journal of Gastroenterology</i> , 2005, 100, 2299-2306.	0.2	192
642	Optimizing Symptom Relief and Preventing Complications in Adults with Gastro-Oesophageal Reflux Disease. <i>Digestion</i> , 2004, 69, 9-16.	1.2	21
643	A 10-day levofloxacin-based therapy in patients with resistant infection: A controlled trial. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 997-1002.	2.4	80
644	Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux. <i>Digestive and Liver Disease</i> , 2004, 36, 565-569.	0.4	75
645	PPI-based triple therapy in the eradication of H. pylori infection. <i>Gastroenterology</i> , 1999, 117, 746-747.	0.6	12
646	Effect of one-month treatment with nonsteroidal antiinflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. <i>Digestive Diseases and Sciences</i> , 1998, 43, 459-463.	1.1	18
647	Evaluation of 24-hour gastric acidity in patients with hepatic cirrhosis. <i>Journal of Hepatology</i> , 1996, 25, 152-157.	1.8	21
648	Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. <i>Gastrointestinal Endoscopy</i> , 1996, 44, 700-705.	0.5	135

#	ARTICLE	IF	CITATIONS
649	A Comparison of Five Maintenance Therapies for Reflux Esophagitis. <i>New England Journal of Medicine</i> , 1995, 333, 1106-1110.	13.9	542
650	Improvement in Esophageal Motor Abnormalities in Systemic Sclerosis Patients Treated with Cyclosporine: Comment on the Article by Clements et al. <i>Arthritis and Rheumatism</i> , 1994, 37, 301-302.	6.7	21
651	Antisecretory effects of three omeprazole regimens for maintenance treatment in duodenal ulcer. <i>Digestive Diseases and Sciences</i> , 1994, 39, 1473-1482.	1.1	5
652	Variability in individual response to various doses of omeprazole. <i>Digestive Diseases and Sciences</i> , 1994, 39, 161-168.	1.1	38
653	Twenty-four Hour Control of Gastric Acidity by Twice Daily Doses of Placebo, Nizatidine 150 mg, Nizatidine 300 mg, and Ranitidine 300 mg. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 70-74.	1.0	8
654	Duration of Acid Suppression in H <sub>2</sub> -Antagonist Nonresponders. <i>Digestion</i> , 1992, 51, 185-192.	1.2	6
655	Comparison of the Effects of Placebo, Ranitidine, Famotidine and Nizatidine on Intra-gastric Acidity by Means of Continuous pH Recording. <i>Digestion</i> , 1989, 42, 1-6.	1.2	25
656	Global Prevalence of Chronic Idiopathic Constipation According to the Rome Criteria: Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
657	Prevalence of Anxiety and Depression in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0